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ABSTRACT  
Shigella is an enteric pathogen that is the most common bacterial cause of dysentery 
globally, most frequently infecting children in developing countries. Resistance to 
common antimicrobials is now widespread and is beginning to make the management of 
this often-severe infection very challenging. Vaccination offers a realistic option for 
preventing and controlling shigellosis, yet several critical questions need to be answered 
before a successfully licensed vaccine can be introduced. Ho Chi Minh City (HCMC), in 
Vietnam, is a rapidly industrialising urban setting with a high burden of paediatric 
diarrhoeal disease and is representative of many similar regions globally. 
Through the structure of a community cohort, the incidence of diarrhoeal disease in 
children under the age of five in HCMC was found to be 70/100 child years, indicating 
that diarrhoea remains a significant cause of paediatric morbidity in this location. 
Furthermore, children living at low elevation in the centre of the city were found to be at 
increased risk of reported diarrhoeal disease during periods of higher temperature and 
flooding, highlighting a particular community at risk. This work also documents Shigella 
as a common cause of dysentery in both hospital and the community in HCMC, with 
community-based incidence estimated to be 1.5/100 child years in 2-5 year olds.  
Resistance against a variety of antimicrobials in Shigella was detected, and organisms 
harbouring mutations against fluoroquinolone activity were found to survive for longer 
periods in the presence of ciprofloxacin in vitro, suggesting a potential epidemiological 
advantage against sensitive strains. Finally, the half-life of maternal immunity against the 
O-antigen of S. sonnei was found to 43 days and by five months of age less than half of 
children in HCMC have any circulating maternal protection. Work from this thesis will 
help inform future vaccine rollout efforts and fills important gaps in the current literature 
surrounding this increasingly challenging infection.  
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1 INTRODUCTION 
1.1 Diarrhoea 
Each year, 10% of all child deaths globally are attributable to diarrhoeal disease [1]. With 
over  700,000 deaths and1.7 billion episodes annually [1,2], diarrhoea remains a 
significant public health challenge in young children in industrialising regions [3,4]. The 
Millennium Development Goals (MDGs) called for a reduction in child mortality by two 
thirds between 1990 and 2015. Although recent analyses have shown that both mortality 
and morbidity due to diarrhoeal disease are declining globally [1,5], some regions still 
report unacceptably high rates in children [5]. Furthermore, antimicrobial resistance 
(AMR) in some enteric bacterial pathogens is threatening to slow recent progress in 
tackling this complex and multifaceted syndrome [6,7].   
Diarrhoea is defined by the WHO as the passage of unusually loose or watery stools, 
usually at least three times in a 24 hour period [8]. Severity of a diarrhoeal episode is 
generally assessed by presence and severity of dehydration, bloody stools, persistent 
diarrhoea and/or malnutrition [8]. The recent Global Enteric Multicenter Study (GEMS) 
evaluated the aetiology and population-based burden of moderate to severe diarrhoea 
(MSD) in >9,000 children in seven developing countries for global policy planning 
purposes [9]. They define MSD as diarrhoea accompanied by either (1) dehydration to a 
degree that the child’s survival would likely depend on access to life-saving rehydration 
fluids or (2) evidence of inflammatory destruction of the intestinal mucosa [10].  
Diarrhoeal disease in young children can be due infection with a number of pathogens, 
the aetiology of which is dependent on factors such as age, season and nutrition status 
[3,4,11,12]. Rotavirus is the most common cause of diarrhoeal disease in the first two 
years of life globally [3,4]. Prior to introduction of rotavirus vaccines, roughly 450,000 
children died each year of rotavirus diarrhoeal disease [13]. Yet after successful 
endorsement by WHO in the late 2000s, 77 countries now include rotavirus vaccine in 
their national immunisation programs and consequently, reported rotavirus incidence has 
fallen dramatically [14,15]. The nature of this success draws attention to the relative lack 
of progress against other diarrhoeal aetiologies, particularly those causing dysentery 
[16], a syndrome associated with structural and functional intestinal damage as well as 
greater endogenous protein loss compared to non-dysenteric diarrhoea [17]. Pathogens 
known to cause bacillary dysentery in children under five years of age include primarily 
Shigella spp. but also Campylobacter spp. and enteroinvasive Escherichia coli (EIEC) 
[3,4]. 
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1.2 Shigella 
Shigella are a genus of faecal-orally transmitted Gram-negative enteric bacteria of the 
Enterobacteriaceae family that are responsible for >100,000 deaths and seven million 
disability adjusted life years (DALYs) annually [18,19]. Of all of the bacterial pathogens 
that cause diarrhoea, Shigella is of particular concern for several reasons. First, its low 
infectious dose (as few as 10-500 organisms) [20] allows it to spread quickly via person-
to-person contact in crowded settings with poor hygiene, highlighted by outbreaks in 
locations such as daycares and refugee camps [21–24]. Secondly, the clinical severity of 
Shigella can result in life threatening infections and subsequent growth retardation, 
particularly in children [25,26]. Lastly, Shigella have displayed remarkable levels of 
antimicrobial resistance (AMR) [27–33], complicating treatment options.  
Two recent large-scale studies showed that Shigella remains one of the most commonly 
isolated diarrhoeal pathogens in children aged under five years in industrialising regions 
of Asia, Africa and South America [3,4]. Shigella was among the top four pathogens 
identified in young children in the GEMS study, and was the most frequently isolated 
pathogen in children aged 24-59 months [3]. Furthermore, from the Malnutrition and 
Enteric Disease study (MAL-ED), a cohort study evaluating >2,100 children in eight 
developing countries for the first two years of life, Shigella was responsible for a 
considerable attributable fraction of diarrhoea (4%, 95% confidence interval (CI): 3.6-
4.3%) amongst the 12-24 month olds [4]. Within Southeast Asia, though data are more 
scarce, Shigella is ubiquitous with incidence rates per 1,000 per year estimated to be 
4.0, 18.6 and 4.9 for Thailand, Indonesia and Vietnam, respectively [34].  
1.2.1 Historical Context 
Epidemics of dysentery were very common throughout history, particularly in militaries 
during times of war as the often unhygienic, overcrowded conditions facilitated rapid 
bacterial spread [16,35]. Shigella was first identified by Dr Kyoshi Shiga in Japan in 1898 
following an epidemic in the country that infected >91,000 people with a mortality rate of 
>20% [36]. Dr Shiga isolated specifically Shigella dysenteriae, one of the four species of 
Shigella and the species most often identified in large, explosive outbreaks [24]. In the 
1940s, Ewing proposed classifying these species into a new genus called Shigella (S. 
dysenteriae, S. flexneri, S. sonnei and S. boydii) based on the O antigen only, because 
Shigella lack the flagellar H antigen and capsular K antigen used in typing E. coli [37,38]. 
Within each species of Shigella there are a number of serotypes based on the diversity 
in structure of the terminal O polysaccharide of the lipopolysaccharide (LPS), a primary 
17 
 
Shieglla virulence factor [39,40]. Within S. dysenteriae there are 15 serotypes, within S. 
flexneri there are 14, within S. boydii there are 20 and S. sonnei only has 1 serotype [41]. 
Of the four species of Shigella, S. sonnei and S. flexneri are most prevalent globally 
[34,42]. S. sonnei is traditionally isolated in resource-rich countries, whereas S. flexneri 
is generally associated in industrialising regions [43,44], though this distribution is 
thought to be changing [45]. While the two species largely share a similar clinical 
phenotype and epidemiological profile [31], the differences between them are only 
beginning to be understood. Phylogeographically the two species have distinct histories. 
The current global population of S. sonnei is now considered to have emerged from a 
single clone after the acquisition of AMR determinants, dispersing globally from Europe 
and replacing local strains within the last 500 years [45]. S. flexneri, however, has been 
recently shown to persistently colonise regions for long periods of time, ranging from 
decades to centuries [46]. Local selective pressure due to antimicrobial use is thought to 
be driving the microevolution of S. sonnei [47], whereas this appears not to be the case 
for S. flexneri [46]. Such insights suggest that the epidemiology of Shigella is changing in 
many regions and will continue to do so in the future, warranting a deeper understanding 
of the epidemiology of the pathogen in regions currently experiencing shifts in Shigella 
species.   
AMR amongst Shigella is known to be elevated in endemic areas [48,49], including 
Southeast Asia [27,50–52]. Yet a growing number of recent reports from countries such 
as the US, South Korea and the Republic of Ireland indicate importation of 
fluoroquinolone-resistant Shigella infections from endemic regions, often with 
subsequent domestic transmission [53–55]. Furthermore, an epidemic of azithromycin-
resistant shigellosis has recently been documented in Europe and North America among 
men who have sex with men (MSM) [56]. Such trends indicate that shigellosis, 
particularly AMR strains, is becoming a public health concern not only in industrialising 
regions but globally.   
1.2.2 Clinical Presentation 
The symptoms of shigellosis can range from mild watery diarrhoea to severe 
inflammatory bacillary dysentery; severity is suggested to correspond to bacterial load 
[57].  After an incubation period of 12 hours to two days, symptoms appear abruptly and 
include a short period of watery diarrhoea with intestinal cramps and general malaise, 
followed by fever, tenesmus and eventual emission of bloody, often mucopurulent stools 
[25]. Damage to the gut mucosal surface results in enterocyte death and the 
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characteristic mucosal ulcerations of bacillary dysentery [58]. The infection can progress 
to life-threatening in the immunocompromised, malnourished, very young or if adequate 
medical treatment is not available [16,59–61]. Death in early stages of the disease is due 
most often to septicaemia, toxic megacolon or renal failure [62–64]. Bacteremia is rare 
but has a high mortality rate when reported [25,65,66]. 
Shigella infections are associated with poor physical development in children, including 
decreased linear growth [26]. Repeat and persistent diarrhoeal infections are known to 
have dramatic effects on intestinal absorption, resulting in intestinal enteropathy and 
malnutrition [67]. This, in turn, renders the child more susceptible to future diarrhoeal 
infections and can lead to impaired physical and cognitive growth and increased risk for 
long-term chronic morbidities later in life, particularly in impoverished areas [68,69].  
1.2.3 Pathogenesis 
The Shigella are recently emerged clones of Escherichia coli, which have adopted an 
intracellular, pathogenic lifestyle [70]. This shift to intracellularity was due to the recent 
and independent acquisition of an invasion plasmid (pINV), the first of which were 
acquired ≤300,000 years ago [70,71]. Shigella has undergone purifying selection as a 
function of niche specialisation as it has lost traits such as catabolic pathways and 
flagellar proteins that are no longer required once surviving intracellularly [70–72]. 
Shigella are also able to acquire and transfer plasmids that are critical for pathogenesis, 
the accumulation of which were important steps in the diversification from their non-
pathogenic E. coli ancestors [59].  
The virulence plasmid and associated virulence genes are an essential determinant of all 
Shigella as they provide for tissue invasion as well as an intracellular lifestyle [73]. These 
virulence genes are under tight control of a regulator network that responds to 
environmental changes. The major trigger inducing the expression of the virulence 
plasmid is a temperature shift to 37°C [74]. Once ingested, Shigella invades the gut 
epithelial cells through the antigen-sampling microfold cells (M cells) in the colon [75,76], 
as shown in Figure 1. The bacteria are then phagocytosed by resident macrophages and 
dendritic cells in the lymphoid follicle. Shigella evades degradation by rapidly escaping 
from the phagocytic vacuole in the macrophage by destroying the phagosomal 
membrane via the invasion plasmid antigen (Ipa) IpaB [77]. Following escape, Shigella 
induces apoptotic cell death of the macrophage [78]. This leads to the release of 
proinflammatory cytokines (interleukin (IL)-1β and IL-18) which stimulate a strong 
intestinal inflammatory response [59].  
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Figure 1: Shigella invasion of gastrointestinal epithelium. Ipa: Invasion plasmid antigen; LPS: 
lipopolysaccharide; NK: Natural Killer; PMN: Polymorphonuclear cell; sIgA: Secretory IgA; TTSS: 
Type 3 secretion system. Take from: Camacho AI, Irache JM, Gamazo C. Recent progress 
towards development of a Shigella vaccine. Expert Rev. Vaccines 2013; 12:43–55. 
Once the organism has escaped the macrophage, the bacteria then gain access to the 
basal surface of the enterocytes, where it uses a type 3 secretion system (T3SS) to 
invade the host cell and replicate in the cytoplasm [73]. To invade the enterocyte, the 
needle of the T3SS (formed of proteins IpaB, IpaC and IpaD) is inserted into the host cell 
and forms a pore through which other proteins are transported [79]. T3SS enables the 
translocation of ~25 effector proteins from the bacterial cytoplasm directly to the 
eukaryotic host cell where they interfere with a variety of host cell processes [80,81]. 
After T3SS insertion, the membrane of the enterocyte starts to ruffle due to the effector-
mediated induction of actin polymerisation and forms a macropinocytic pocket that 
encloses the bacteria [59]. The bacteria is then trapped in a phagosome after uptake, 
which it quickly lyses and escapes into the cytosol via effector proteins IpaB, IpaC and 
IpaD [82,83].The cytoplasm of the enterocyte is the main replicative niche for Shigella, 
which is relatively unique among enteric bacteria [70]. 
Shigella do not have flagella and are therefore non-motile. They instead rely on an 
elaborate mechanism to hijack the host cytoskeleton via the plasmid encoded protein 
IcsA which localises to one pole of the bacterium [84]. IcsA (also known as VirG) initiates 
localised actin polymerisation, which results in actin cross-linking and contraction and 
provides a propulsive force which is energised by ATP [85]. Intracellular motility is also 
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dependent on the T3SS substrate IcsB, which protects the bacteria from being 
recognised and entrapped by the host cell autophagy machinery [86]. IcsA also allows 
for the formation of extracellular protrusions that permit cell to cell spread as well as 
intracellular microfilament movement [84]. Shigella is therefore capable of dissemination 
to neighbouring host cells while avoiding exposure to the extracellular host immune 
defences [59,84].  
The immune response to Shigella during the infection process plays a critical role in the 
pathogenesis of the bacteria. A large part of the mucosal inflammatory response in 
Shigella infections is mediated by sensing of bacterial peptidoglycan in the epithelial cells 
[87]. IL-8 is the major chemokine mediating the inflammatory burst and leads recruitment 
of polymorphonuclear cells that cross the epithelial layer by impairing tight junctions 
between the enterocytes, which in turn allows a massive entry of bacteria [88,89]. This 
translocation of the bacteria from the intestinal lumen to the subepithelial lamina propria 
of the colon is considered to be a primary Shigella virulence mechanism as it provides 
for direct access for Shigella to breach the enterocyte [59]. Yet Shigella must carefully 
control the immune response for successful invasion. 
Shigella can modulate the immune response in a number of ways [87]. For example, 
Shigella are able to downregulate the expression of antimicrobial peptides, which are 
important antibacterial effectors constantly released from the mucosal surfaces of the 
gastrointestinal tract [90]. Additionally, an effector called OspG can prevent activation of 
the NF-κB pathway, the heart of the signalling cascade leading to the mucosal immune 
response, to negatively control the host innate immune response upon invasion of the 
epithelium [91]. This initial down-regulation allows Shigella to interact with the intestinal 
epithelium to facilitate colonisation and invasion by an initially low number of luminal 
bacteria [91]. However, once successfully inside of an enterocyte, upregulating 
inflammation is then advantageous for Shigella as it allows for a large number of bacteria 
to enter the lamina propria via broken tight junctions between enterocytes [87].  
1.2.3.1 Toxins 
Shigella can produce several enterotoxins, known as Shigella enterotoxin 1 (ShET1) and 
ShET2 that alter electrolyte and water transport in the small intestine during the initial 
watery phase of the disease [41]. ShET1, encoded by the set genes located on the 
chromosome of many clinical isolates of S. flexneri 2a, induces intestinal fluid 
accumulation and cause net fluid secretion [92–94]. ShET2 is found in many Shigella 
serotypes [95] and is encoded by the sen gene located on the large invasion plasmid 
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[96]. Both of these toxins continue to serve as targets for attenuating mutations in 
vaccine candidates [97–99].  
Shiga toxins (Stx) are potent protein-synthesis inhibitors that target the vascular 
endothelium, including the colon, kidneys and central nervous and can lead to hemolytic 
uremic syndrome (HUS) [100] as well as other life threatening complications [101,102]. 
Furthermore, antimicrobial therapy for infections involving Stx have been associated with 
an increased risk of HUS [103]. Stx1 is a cytotoxic protein made by primarily S. 
dysenteriae 1 and can also be found Shiga-toxin producing E. coli (STEC) [101]. In S. 
dysenteriae 1 the genes encoding the toxin (stxA and stxB) are found on the 
chromosome [104]. Stx1 is traditionally not found in other serotypes or species of 
Shigella [59] and is not required for virulence [16]. However, alarmingly, there are recent 
reports of phage-mediated Stx-producing S. flexneri and S. sonnei infections from a 
disparate number of locations, including Haiti and the USA [105,106]. 
1.2.3.2 Shigella and Enteroinvasive E. coli (EIEC) 
EIEC and Shigella are taxonomically indistinguishable at a species level [107] and share 
similar pathogenic mechanisms and biochemical characteristics [59,108]. The two 
bacteria are traditionally distinguished by minor biochemical properties [107]. Though 
EIEC normally elicits watery diarrhea [109], it can also cause dysentery [110]; the 
infective dose of EIEC is far larger (~108 organisms) [111,112] compared to Shigella (10-
500 organisms) [20].  Like Shigella, EIEC strains have a virulence plasmid that allows for 
invasion of epithelial cells and cell-to-cell dissemination [113]. While EIEC and Shigella 
share a large number of virulence genes [107,113], phylogenetic analyses suggest that 
Shigella and EIEC evolved independently and EIEC as a group cannot be considered as 
the ancestor to Shigella [108]. However, recent whole genome sequencing analyses 
have provided evidence to suggest that Shigella belong in the E. coli genus and share 
the same pool of genes. Therefore, many argue that the Shigella genus should be 
moved back within the species of E. coli, classified as EIEC and renamed using the 
common O antigen naming system of E. coli [108,114,115]. Yet due to its clinical 
severity, others have favoured the traditional nomenclature separating the Shigella 
genus from E. coli [107]. 
1.2.4 Antimicrobial Resistance 
AMR among Shigella and other Gram-negative pathogens represents one of the 
challenges currently facing paediatricians in developing regions [6]. Though the WHO 
explicitly recommends that antimicrobials not be used routinely for the treatment of 
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paediatric diarrhoea [8], the exception is in the case of shigellosis, with current guidelines 
recommending the fluoroquinolone ciprofloxacin, followed by second line therapies 
pivmecillinam, ceftriaxone and azithromycin [116]. Reduced susceptibility and often full 
resistance to these antimicrobials is now reported amongst Shigella isolates in many 
regions globally [27–33,48,49,117,118].  
The mechanisms of antimicrobial resistance in Shigella are diverse. Several 
mechanisms of quinolone resistance, for example, have been identified amongst 
Shigella and the Enterobacteriaceae family. The quinolones and fluoroquinolones target 
the bacterial enzymes DNA gyrase (gyrA and gyrB genes) and topoisomerase IV (parC 
and parE genes) that are essential for bacterial replication. The bacteria may acquire 
chromosomal mutations in the quinolone resistance determining region (QRDR) that 
includes gyrA, gyrB, parC and parE, altering the target of the drug [30,119,120]. Shigella 
can also acquire plasmid-mediated quinolone resistance (PMQR) such as qnr genes, 
which encode pentapeptide repeat proteins that bind to and protect DNA gyrase and 
topoisomerase from the action of fluoroquinolones. Plasmids containing genes for an 
aminoglycoside acetyltransferase that is capable of acetylating and reducing the activity 
of fluoroquinolones (aac(6’)-Ib-cr) as well as those containing genes upregulating efflux 
pump activity (tolC) have also been documented in Shigella [121–125]. The MIC against 
fluoroquinolones generally rises with an increasing number of resistance determinants 
[126].  
1.2.5 Immune Response & Vaccines 
During infection with Shigella, the host adaptive immune response targets the LPS O-
side chain, the major bacterial surface antigen, which is serotype specific [127–133]. 
Infection with wild-type or experimental Shigella confers protective immunity and 
prevents disease during subsequent exposures of the same serotype [130,134–136] with 
one cohort study in Chile estimating 72% protection against homologous serotype 
reinfection [127]. Although not considered a definitive correlate of immunity [137], it has 
been shown that serum anti-LPS is a strong marker of acquired immunity and that lack of 
serotype specific antibody is associated with an increased risk for symptomatic disease 
[133,136,138–140]. Both serum IgG and IgA antibodies directed against the O-antigen 
are particularly important and appear 1-2 weeks after primary exposure [132,133,136]. 
[141]. In terms of a cell-mediated response, evidence suggests that CD8+ T cells are not 
required for protective immunity because they fail to be primed as Shigella can impair the 
migration pattern of CD4+ T cells [142,143]. 
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The debate as to whether protection is mediated predominantly via secretory IgA (sIgA) 
or serum IgG or both is contentious [41]. LPS-specific sIgA is the major mucosal 
antibody induced upon natural infection and can survive, anchored by mucus to 
enterocytes, for extended periods in the harsh gastric environment and likely prevents 
colonisation and Shigella-associated inflammation responsible for tissue destruction 
[137,144,145]. Gut-derived O-specific IgA antigen secreting cells are detected in 
peripheral blood 7-10 days after exposure, and are believed to represent a pool of 
transiently migrating antigen-specific B cells with the capacity to home to the gut [141]. 
Measurements of sIgA in mucosal secretions can be variable, however [146]. Shigella is 
also likely inactivated by systemic IgG leaked into the intestinal lumen, possibly through 
complement-mediated lysis [141,147]. Finally, there is known to be a significant rise in 
anti-Ipa antibodies after natural exposure and experimental infections and in endemic 
areas anti-Ipa titers have been shown to increase with age [132,138,139]. It is thought 
that in addition to anti-LPS antibodies, anti-Ipa antibodies also play a significant role in 
protection [141]. 
Vaccination still offers the greatest hope of an effective and sustainable strategy to 
control shigellosis and significantly reduce the burden of disease [148,149]. The WHO 
has listed Shigella, along with enterotoxigenic E. coli (ETEC), among the top candidates 
on its vaccine development priority list [67,149]. Although a considerable number of trials 
have been conducted on a variety of Shigella vaccine candidates since the1960s [150], 
none have yet proved both safe and effective [41].  
1.2.5.1 Conjugate and subunit vaccines 
As protection against Shigella is serotype specific, one major route of vaccine 
development has focused on the immunogenicity of the serotype specific LPS [149]. 
Parenteral conjugate vaccines pursuing this serotype-specific protection strategy linking 
Shigella LPS to a carrier protein have received much attention [147], and have been 
trialled with some success [151,152]. Although LPS alone is poorly immunogenic [153], 
when covalently coupled to protein carriers it can induce a stronger and longer-lasting T 
cell-dependent immune response [154]. A multivalent candidate including S. sonnei and 
S. flexneri serotypes 2a, 3a and 6 and possibly S. dysenteriae 1 would provide protection 
against the bulk of infections worldwide [141,155], with cross-protection against an 
additional 11 S. flexneri serotypes [42].  
One candidate vaccine, S. sonnei LPS conjugated to the Pseudomonas exoprotein A 
(rEPA) was shown to be efficacious in Israeli soldiers [156,157] but did not show efficacy 
24 
 
in Israeli children under two years of age in further trials [152]. The Walter Reed Army 
Institute of Research has developed a subunit candidate called Invaplex using Ipa 
proteins linked to serotype-specific LPS which has proven safe and immunogenic after 
intranasal delivery in healthy volunteers [158,159]. Invaplex is currently in a phase 1 trial 
in healthy adults [160]. Additionally, candidate conjugate vaccines using synthetic LPS 
conjugated to tetanus toxoid have also been developed in recent years as well, although 
are yet to be experimentally tested in humans [161,162]. It has been suggested that 
conjugate vaccines would be maximally protective when administered to individuals 
previously mucosally primed to elicit mucosal as well as systemic responses [149].  
1.2.5.2 Live attenuated vaccines 
Molecular engineering of Shigella genomes led to the generation of live, attenuated, oral 
Shigella vaccine candidates with defined deletions and mutations in specific virulence or 
metabolic genes. This strategy delivers a high level of antigen exposure, typically 
induces a large immune response but can prove to be reactogenic in addition to the risk 
of reversion [137]. The Center for Vaccine Development at the University of Maryland 
has developed several iterations of an attenuated S. flexneri 2a strain, first generating a 
ΔvirG (alternate name for IcsA) ΔaroA candidate that inhibited intracellular movement 
and disrupted a metabolic process which proved too reactogenic [163], followed by a 
candidate with similar motility and metabolic mutations (ΔvirG, ΔguaBA) in addition to 
mutated ShET toxin genes (Δsen, Δset) which proved to be over-attenuated [164]. They 
then produced a ΔguaBA (metabolism),  Δsen, Δset mutant with an encouraging safety 
and efficacy profile [99]. 
Meanwhile, the Walter Reed Army Institute of Research with Johns Hopkins University 
have developed an attenuated S. flexneri 2a candidate with impaired intracellular 
movement (ΔvirG) which was safe and effective in North American volunteers, but failed 
to induce an immune response in Bangladeshi children [165,166], potentially due to low 
availability of intestinal iron in the Bangladeshi population [149]. However, ‘second 
generation’ ∆virG mutants with additional deletions in ShET genes are under 
development and early clinical evaluation [167–170]. Finally, a S. sonnei candidate with 
ΔvirG, Δsen, Δset has proved to be safe and immunogenic in primates [170]. 
1.2.5.3 Inactivated whole cell vaccines 
Although historically difficult to balance immunogenicity and safety in killed whole cell 
vaccines [167], formalin-inactivated S. sonnei and S. flexneri candidates have been 
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shown to be safe and immunogenic in North American volunteers [171,172]. Efficacy 
studies are now required [141]. 
1.2.5.4 Vaccine challenges 
Several barriers continue to slow the pace of Shigella vaccine development including 
undefined correlates of immunity, a lack of a good small animal model, difficulty in 
providing broad coverage and continuing economic and political challenges [141,173]. 
Enteric vaccines as a whole are hindered due to limited knowledge of gut immune 
function in children, lack of mucosal adjuvants and a limited understanding of why 
mucosal vaccines fail in industrialising regions [145]. Efficacy of enteric vaccines in 
children in developing countries, particularly mucosal vaccines, is notoriously low 
compared to many developed countries [174–176]. Environmental enteropathy is thought 
to contribute substantially to reduced immunogenicity in children from poor areas, with 
explanations including blunted villi, heightened inflammation due to concurrent parasite 
infection, small bowel overgrowth, malabsorption, caloric and micronutrient deficiencies 
(including vitamin A and zinc) and increased gut permeability and bacterial translocation 
[12,145,177,178]. Furthermore, there is likely to be interference from maternal 
antibodies, acquired both transplacentally and via breastmilk [179–181]. 
Parenteral vaccines are generally poor inducers of mucosal immunity and less effective 
against enteric pathogens [137]. However, mucosal vaccines face great challenges in 
addition to environmental enteropathy of a child host in a developing country. Mucosal 
immune regulation is designed to prevent inadvertent immune responses to dietary or 
environmental antigens [173,182], and therefore stimulating it sufficiently is often 
challenging. Additionally, mucosal vaccines can be diluted in mucosal secretions, 
captured in mucus gels or attacked by proteases so relatively large doses of vaccine are 
required, though it is not possible to determine how much vaccine crosses the mucosa 
after administration [183]. A mucosal adjuvant and delivery system would be 
advantageous [145], particularly as alum cannot be used orally [137]. Furthermore, use 
of antimicrobials, anti-inflammatory agents, probiotics, deworming pills, vitamin A or 
drugs modulating gut permeability may improve mucosal vaccine performance in 
industrialising countries [145,178]. 
Optimal protection against Shigella will likely require both systemic and mucosal 
responses and the multifactorial nature of virulence indicates the vaccine will likely need 
to have a number of antigens [137]. An ideal Shigella vaccine would be temperature-
resistant and administered as a single dose infant vaccine integrated into the Expanded 
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Programme on Immunization (EPI) [177], although oral vaccination is known to be most 
effective when given in multiple doses [184]. Oral vaccines induce stronger mucosal 
immune responses and tend to be more accepted by parents than parenterally delivered 
vaccines. Mucosal vaccines also reduce issues surrounding needles and highly trained 
healthcare professionals [178,183,185], are generally easier to manufacture [145], and 
make mass campaigns easier [178]. However, live attenuated Shigella vaccines have 
suffered from problems with reactogenicity [163,164]; it has been suggested that the 
ability of a vaccine to invade may be a prerequisite for induction of effective immunity, 
which requires a careful balance between immunogenicity and reactogenicity [182].  
1.3 Vietnam: background and diarrhoeal disease burden 
As recently as the 1980s, Vietnam was considered one of the poorest countries on earth 
[186]. Yet it has emerged from war and famine to make remarkable progress in 
economic development since it reopened for international investment in the early 1990s 
[187,188]. It has a GDP per capita on par with the Philippines and Indonesia [189], and 
was recently upgraded from a low income country to a lower-middle income country by 
the World Bank in 2012 [190]. Vietnam is now a rapidly industrialising country with an 
urbanising population of 90 million people and a Gross National Income (GNI) per capita 
of US $1,740 [191]. Ho Chi Minh City (HCMC) is the largest city in Vietnam, with an 
official population of approximately eight million people [192]. HCMC is located in the 
tropical south of the country, with an average annual temperature of 28oC and total 
yearly rainfall of almost two meters [193], which falls during the rainy season of May-
November.  
Vietnam on the whole has made excellent progress in healthcare in recent decades, with 
life expectancy in men and women rising from 66 and 72 years, respectively, in 1990 to 
72 and 80 years, respectively, in 2013 [5]. Additionally, under-five mortality has fallen 
from 51/1000 live births in 1990 to 24/1000 live births in 2012 [194]. Behind this rapid 
advancement lies a growing wealth disparity, however, particularly among rural and 
urban poor populations [188,195]. Under-five mortality and prevalence of children who 
are underweight, for example, are highest in the poorest quintile of the population 
[188,196]. Vietnam is also currently undergoing an epidemiological transition whereby 
deaths due to non-communicable disease are growing yet those due to infectious causes 
are still significant in number [5,197]. Such a complex transition has dramatic 
implications for public health policy planning and resource allocation in the country. 
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Healthcare expenditure makes up roughly 6% of the gross domestic product of Vietnam, 
with national public health insurance accounting for 30% and private expenditure making 
up 70% in 2014 [198]. Though the government are aiming to provide free nationalised 
health insurance for all citizens [199], as was done prior to 1989 [198], only 60% of the 
population was covered in 2011 [199]. In June 2014 the national assembly passed an 
insurance law designed to make participation compulsory [200], though Vietnam still 
relies heavily on out-of-pocket payments to finance health care with a high fraction of 
Vietnamese households experiencing catastrophic and/or impoverishing out-of-pocket 
payments [201]. Public hospitals in Vietnam are often overcrowded, particularly in urban 
areas, and struggle to cope with high patient demand. The government legalised private 
hospitals in 1999 in an effort to reduce pressure on state-funded hospitals, though they 
contribute less than 5% of all hospital beds in the country [202]. 
EPI vaccinations have made a substantial impact on childhood mortality and have been 
very cost effective in Vietnam [203], with an estimated 95% of children covered by 3 
doses of diphtheria-tetanus-pertussis vaccine and 94% covered by two doses of measles 
vaccine in 2014 [204]. The prevalence of childhood malnutrition in Vietnam was 
estimated to be 15% in 2013, ranking high among Asian countries [205]. From a large, 
recent study evaluating nutrition across several sites Vietnam, approximately 24% of 
children aged 5 are stunted (height-for-age Z score <-2) [206]. The HIV prevalence in the 
country is low, with 0.5% of the adult  population aged 15-49 positive [207]. A total of 
67% of the Vietnamese population are live in rural areas [191], though the country is 
rapidly  urbanising [208]. 
Diarrhoea is a leading cause of paediatric morbidity and mortality in Vietnam, which has 
an estimated diarrhoeal incidence of 11.5/100/year in children under five years [34,194]. 
A nationwide survey published in 2008 indicated that the burden of shigellosis in Vietnam 
remains unacceptably high [209]. Shigella patients have been shown to present 
frequently in hospital in HCMC [31] and a population-based study in central Vietnam 
estimated an incidence of 490/100,000/year in children under five years [34]. Previous 
work has shown that, as in other developing nations, Shigella tends to peak in the 
summer months during the rainy season [31,209] and is most frequently identified in 
children aged two to three years in Vietnam [31,34,210]. Spatial risk analysis has 
identified potentially different ecological niches between S. flexneri and S. sonnei in 
central Vietnam [211]. One study exploring a collection of Shigella isolates from 
hospitalised children found that shigellosis patients were likely to live in areas of HCMC 
associated with high population density and poor sanitation [31].  
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The species shift from S. flexneri to S. sonnei has been dramatic in Vietnam. In 1995-96, 
for example, only 30% of Shigella isolates from children admitted to hospital in HCMC 
were S. sonnei compared with 70% by 2007-2008 [31]. It is thought that a multidrug 
resistant (MDR) S. sonnei clone entered Vietnam in the early 1980s and then spread 
geographically around the country, originating in HCMC and evolving locally due to 
selection for MDR through gene transfer within the locally available accessory gene pool 
[47]. Previous work indicates that it is the expansion of a single successful MDR clone of 
S. sonnei, rather than a generalised increase in various strains, which is replacing S. 
flexneri as the predominant species in Vietnam [47].   
1.4 Gaps in knowledge 
Shigella is a consistent problem in areas of poor sanitation infrastructure and may 
emerge as a global public health problem due to international travel and AMR. 
Vaccination offers a realistic option for combating this challenge [148]. However, in order 
to effectively roll out a Shigella vaccine in the future there are still several critical 
questions that need to be answered. Firstly, reliable community estimates of diarrhoea 
and Shigella incidence in young children in endemic regions, particularly where S. sonnei 
is thought to be emerging, are lacking. Accurately quantifying the burden of disease 
through active surveillance is necessary to evaluate the future demand for such a 
vaccine. Secondly, maternal immunity against Shigella in infancy is extremely ill-defined. 
If a future vaccine can be administered at some point in the first year of life in the EPI 
schedule, it is important to understand the dynamics of maternal immunity to ensure that 
the timing of a Shigella vaccine is appropriate.  
In the absence of a licensed vaccine, optimising treatment regimens would provide 
physicians with a more appropriate way of managing infections. Quantifying the 
relationship between fluoroquinolone resistance and clinical outcome, for example, may 
help inform treatment policy. Furthermore, investigating risk factors and potential 
transmission routes within an urban, industrialising area may shed light on primary 
routes of transmission in this setting and may illuminate non-vaccine based prevention 
strategies for controlling this increasingly resistant infection. 
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2 AIM, OBJECTIVES, STRUCTURE & CONTRIBUTIONS 
 
2.1 Aim 
The principal aim of the thesis is to quantify the burden of both diarrhoea generally and 
paediatric Shigella diarrhoeal infections specifically in HCMC, Vietnam to determine 
whether a Shigella vaccine would be necessary in this setting. 
2.2 Objectives 
In order to define the burden of diarrhoeal disease and determine the need of a Shigella 
vaccine in HCMC, several major avenues of investigation will be pursued. The specific 
objectives of the thesis include:  
1) Describe the aetiology of diarrhoea in HCMC 
2) Define the spatiotemporal trends of diarrhoea in HCMC 
3) Quantify the age-specific burden of both diarrhoea and Shigella infections in the 
community in children under five years of age 
4) Define the duration of maternal antibody against Shigella in infancy 
5) Evaluate the impact of fluoroquinolone resistance on clinical outcome of Shigella 
patients 
By performing the listed objectives, a greater understanding of the burden of diarrhoea in 
HCMC will be generated. An accurate, up to date description of the aetiology and burden 
of diarrhoea, evaluated through hospital-based and communities studies, will provide an 
evaluation as to the relative importance and frequency of Shigella infections in young 
children in this setting. Such burden estimates will be important for evaluating the 
necessity of a vaccine. Next, examining maternal antibody dynamics will provide critical 
information on transfer of antibody from mother to foetus as well as duration of 
circulation of antibody in the infant. Such data are important to inform any vaccination 
schedule should a licensed vaccine become available. Finally, in the event that a vaccine 
is not deemed necessary, developing a more thorough understanding of the risk factors 
for diarrhoeal disease in the community will allow for generation of non-vaccine based 
prevention and control measures. Understanding the impact of antimicrobial resistance 
on therapeutic outcome, for example, will help tailor more appropriate treatment 
regimens in this setting. 
Diarrhoea throughout this thesis refers to the passage of at least three unusually loose 
stools in a 24 hours period or one bloody/mucoid stool [1]. While MSD is a concern 
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globally, the majority of diarrhoeal disease seen in hospitals in HCMC does not meet the 
criteria for MSD (dehydration to a degree that the child’s survival would likely depend on 
access to life-saving rehydration fluids or evidence of inflammatory destruction of the 
intestinal mucosa [2]) [3]. 
2.3 Structure and contribution of research papers 
This PhD is split into two sections. The first examines the aetiology and epidemiology of 
diarrhoea generally, both in hospital and in the community in HCMC. This work was 
conducted to put the burden of Shigella infections (described in part two) into context. 
There are three research papers included in part one. The second section of the thesis 
investigates the burden and characteristics of Shigella infections in Ho Chi Minh City in 
closer detail. Age specific incidence in the community, duration of maternal immunity and 
clinical response to fluoroquinolone therapy are discussed to highlight important 
characteristics of the infection. There are five papers included in part two.    
2.3.1 Part 1: General diarrhoea 
2.3.1.1 Paper 1 
Research paper 1, entitled “A prospective multi-center observational study of children 
hospitalized with diarrhea in Ho Chi Minh City, Vietnam”, was published in the American 
Journal of Tropical Medicine & Hygiene in 2015. This work is the first detailed description 
of the aetiology, clinical manifestations, antimicrobial resistance and prescribing habits 
amongst doctors for both bacterial and viral hospitalised diarrhoea in children under 5 
years of age in Ho Chi Minh City, Vietnam.  
2.3.1.2 Paper 2 
Research paper 2 was published as “The impact of environmental and climatic variation 
on the spatiotemporal trends of hospitalized pediatric diarrhea in Ho Chi Minh City, 
Vietnam” in Health & Place in 2015. This paper examines spatiotemporal variation in 
hospitalised diarrhoeal disease in Ho Chi Minh City and highlights central and southern 
regions of the city to be at increased localised risk of reported diarrhoeal disease due to 
temperature and humidity fluctuations.  
2.3.1.3 Paper 3 
Research paper 3 was published as “The epidemiology and aetiology of diarrhoeal 
disease in infancy in southern Vietnam: a birth cohort study” in the International Journal 
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of Infectious Diseases in 2015. This work quantifies the burden of diarrhoeal disease in 
the first year of life from a birth cohort in Ho Chi Minh City as well as a rural area of the 
Mekong Delta. This cohort, though it employed passive surveillance for diarrhoeal 
disease, offers the first community-based incidence estimates of diarrhoeal disease for 
these locations.   
2.3.2 Part 2: Shigella  
2.3.2.1 Paper 4 
Research paper 4 was published as “The rising dominance of Shigella sonnei: An 
intercontinental shift in the etiology of bacillary dysentery” in PLoS Neglected Tropical 
Diseases in 2015. This review examines reasons for the relative increase in Shigella 
sonnei against S. flexneri in areas traditionally dominated by the latter.  
2.3.2.2 Paper 5 
Research paper 5 was published as “A cohort study to define the age-specific incidence 
and risk factors of Shigella diarrhoeal infections in Vietnamese children: a study protocol” 
in BMC Public Health in 2014. This paper is a protocol describing a longitudinal cohort 
study designed to estimate the age specific incidence of Shigella infections in the 
community in Ho Chi Minh City. Methodology behind the active surveillance of diarrhoeal 
disease is presented along with study rationale, aims and objectives.  
2.3.2.3 Paper 6 
Research paper 6 has been written in preparation for publication and is titled “Active 
surveillance for diarrhoeal disease in the community: incidence of Shigella and other 
enteric infections in Ho Chi Minh City”. This work details results from the first year of the 
longitudinal community cohort study and provides age-specific incidence estimates for 
Shigella as well as a variety of additional aetiologies including norovirus, Campylobacter 
and rotavirus infections. Clinical manifestations, basic risk factors and coinfections from 
the first year of the cohort are discussed in the context of future planned work for data 
and samples from the study.  
2.3.2.4 Paper 7 
Research paper 7 is in press as “The transfer and decay of maternal antibody against 
Shigella sonnei in a longitudinal cohort of Vietnamese infants” in the journal Vaccine in 
2015. In this paper, the duration of maternal immunity against S. sonnei is quantified for 
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the first time and longitudinal measurements of anti-S. sonnei IgG allow estimation of 
when an S. sonnei vaccine should be administered if a successful candidate is licensed 
in the future.  
2.3.2.5 Paper 8 
Research paper 8 is in press as “The clinical implications of reduced susceptibility to 
fluoroquinolones in paediatric Shigella sonnei and Shigella flexneri infections” in the 
Journal of Antimicrobial Chemotherapy. Here, we evaluate differences in clinical 
response between S. sonnei and S. flexneri in treatment with fluoroquinolones for the 
first time. This paper also fills an important gap in the literature by examining in vitro 
growth of Shigella in various concentrations of fluoroquinolones.  
 
2.4 Contributions by candidate and others 
Unless otherwise noted, I, Corinne Thompson, have performed all analyses and written 
all manuscripts included in this thesis. I have not performed any work in the laboratory 
and have shared responsibilities in setting up some of the studies that are included 
herein. I have independently performed all literature reviews and have written the 
introduction and discussion sections of the thesis. Specific contributions to each chapter 
are listed below. 
Paper 1: A prospective multi-center observational study of children hospitalized with 
diarrhea in Ho Chi Minh City, Vietnam 
I am co-first author, along with Dr My VT Phan. Stephen Baker designed the 
study. Dr Phan set up the study at the sites and oversaw sample and data 
collection at the hospitals. Dr Phan performed all laboratory work. I was 
responsible for all data cleaning, management and analysis. I corrected errors in 
the data from source documentation and generated the finalised dataset for 
analyses. Furthermore, I developed all of the STATA code for analysis and R 
code for figures. Dr Phan and I both generated the first draft of the manuscript. I 
created all final tables and figures and was the primary author involved in 
manuscript preparation and submission.  
Paper 2: The impact of environmental and climatic variation on the spatiotemporal trends 
of hospitalized pediatric diarrhea in Ho Chi Minh City, Vietnam 
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I am co-first author, along with Dr Jon Zelner of Columbia University. Stephen 
Baker, Dr Zelner and I designed the study collaboratively. I collated and cleaned 
all of the hospital data (>500,000 records) including overseeing the extensive 
cleaning of the geographic data. I also was responsible for securing the climate 
data from the Vietnamese government. I performed all geostatistical mapping 
analyses. Dr Zelner developed the R code for the mixed effects model and 
goodness of fit evaluations. I wrote the manuscript, prepared all figures and 
tables and was responsible for the submission procedures.  
Paper 3: The epidemiology and aetiology of diarrhoeal disease in infancy in southern 
Vietnam: a birth cohort study 
I am co-first author, along with Dr Katherine Anders. Dr Anders set up the original 
birth cohort study in 2009 and oversaw the management, data and sample 
collection and data management of the entire cohort, including field work and 
laboratory analyses. A number of individuals were responsible for the laboratory 
data (Ms Le Thi Phuong Tu, Ms Tran Thi Ngoc Dung and Ms Nguyen Thi Van 
Thuy). Dr Anders and myself collaborated to design the study together. I cleaned 
and collated all demographic and descriptive data relevant to the diarrhoea study 
from the large database. We both were responsible for cleaning and linking 
diarrhoeal episode data to illness visit records. I developed the STATA code and 
performed the regression analyses. I also performed the geospatial cluster 
analysis. I made all tables in the manuscript and Dr Anders generated Figures 1 
and 2 for the manuscript. I drafted the manuscript and was responsible for the 
submission process.  
Paper 4: The rising dominance of Shigella sonnei: An intercontinental shift in the etiology 
of bacillary dysentery 
I am first author, performed all literature review, generated all figures and wrote 
the manuscript. Pham Thanh Duy performed the antimicrobial susceptibility 
testing and gene content analyses.  
Paper 5: A cohort study to define the age-specific incidence and risk factors of Shigella 
diarrhoeal infections in Vietnamese children: a study protocol 
I am first author. I worked with Stephen Baker on conceiving the design of the 
study, wrote the protocol and patient information materials, and oversaw the 
ethical approval process. I was heavily involved in study set up at the two 
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participating hospitals, including data and sample collection and management. 
Ms Le Thi Quynh Nhi was responsible directly for field work. I wrote the 
manuscript, generated all figures and was responsible for the submission 
process. 
Paper 6: Active surveillance for diarrhoeal disease in the community: incidence of 
Shigella and other enteric infections in Ho Chi Minh City 
I am first author. Stephen Baker and I worked together to design the study. I 
wrote the first draft of the protocol, was heavily involved in ethical approval 
processes, led the daily management of the cohort study and oversaw data and 
sample management. I was responsible for database cleaning and development 
of analysis plans. I wrote the STATA code for all analyses and the R code for all 
figures. Ms Ha Thanh Tuyen and Mr Voong Vinh Phat performed all laboratory 
work. Ms Le Thi Quynh Nhi was directly responsible for field work. I wrote the 
manuscript.  
Paper 7: The transfer and decay of maternal antibody against Shigella sonnei in a 
longitudinal cohort of Vietnamese infants 
I am first author. I led the management of the cohort study, oversaw data 
collection and management and cleaned all data for this manuscript. I developed 
the analysis and code in STATA and R, with assistance from Dr Phung Khanh 
Lam in the OUCRU Biostatistics Department. Ms Le Thi Phuong Tu performed all 
ELISAs. I made all tables and figures, wrote the manuscript and was responsible 
for submission of the work.  
Paper 8: The clinical implications of reduced susceptibility to fluoroquinolones in 
paediatric Shigella sonnei and Shigella flexneri infections 
I am first author. Stephen Baker designed the study. I cleaned and analysed the 
primary data. I wrote the code for analysis in STATA and R with assistance from 
Dr Nguyen Duc Anh in the Biostatistics Department at OUCRU. Ms Ha Thanh 
Tuyen was responsible for all laboratory work. Dr Ha Vinh was responsible for the 
randomised controlled trial and field work. I made all tables and figures for the 
work. I wrote the manuscript and was responsible for the submission.  
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4.1 Supporting Information 
 
Title: The impact of environmental and climatic variation on the spatiotemporal trends of 
hospitalized pediatric diarrhea in Ho Chi Minh City, Vietnam 
 
Tables 
 
Supplementary Table 1: District labels used in manuscript and district names of Ho Chi Minh 
City, Vietnam 
District 
Label 
District Name 
1 1 
2 2 
3 3 
4 4 
5 5 
6 6 
7 7 
8 8 
9 9 
10 10 
11 11 
12 12 
13 Bình Chánh 
14 Bình Tân 
15 Bình Thạnh 
16 Cần Giờ 
17 Củ Chi 
18 Gò Vấp 
19 Hóc Môn 
20 Nhà Bè 
21 Phú Nhuận 
22 Tân Bình 
23 Tân Phú 
24 Thủ Đức 
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Supplementary Table 2: District level effects of humidity (%), flooding (cm above or below mean), rainfall (mm) and temperature (⁰C), relative risks (RR) 
and 95% confidence interval (CI) scaled to standard deviation of each mean-standardized climate variable.   
District 
Humidity Flooding Rain Temperature 
RR 95%CI RR 95%CI RR 95%CI RR 95%CI 
1 0.972 0.955 , 0.989 0.985 0.967 , 1.002 1.007 0.985 , 1.029 0.992 0.981 , 1.004 
2 0.975 0.957 , 0.993 0.991 0.973 , 1.009 1.019 0.997 , 1.043 0.999 0.987 , 1.011 
3 0.960 0.941 , 0.979 0.992 0.974 , 1.011 1.012 0.988 , 1.036 0.993 0.981 , 1.006 
4 0.938 0.921 , 0.956 0.990 0.972 , 1.008 0.998 0.976 , 1.021 0.982 0.970 , 0.995 
5 0.974 0.954 , 0.994 1.004 0.984 , 1.023 1.001 0.977 , 1.026 1.008 0.994 , 1.021 
6 1.012 0.993 , 1.030 1.024 1.006 , 1.043 0.989 0.967 , 1.012 1.035 1.022 , 1.048 
7 0.952 0.935 , 0.968 1.006 0.988 , 1.024 0.997 0.976 , 1.019 0.997 0.985 , 1.009 
8 1.032 1.016 , 1.049 1.038 1.020 , 1.056 0.982 0.962 , 1.001 1.051 1.039 , 1.063 
9 0.946 0.929 , 0.964 1.003 0.985 , 1.022 0.976 0.955 , 0.999 0.991 0.979 , 1.003 
10 0.966 0.947 , 0.986 1.006 0.987 , 1.025 0.996 0.972 , 1.020 1.005 0.992 , 1.019 
11 0.956 0.936 , 0.976 0.998 0.979 , 1.018 1.026 1.000 , 1.051 1.001 0.987 , 1.014 
12 0.960 0.945 , 0.976 0.989 0.972 , 1.006 1.006 0.986 , 1.027 0.992 0.981 , 1.003 
13 0.993 0.976 , 1.010 1.034 1.015 , 1.052 0.993 0.972 , 1.014 1.034 1.022 , 1.047 
14 1.004 0.988 , 1.021 1.018 1.001 , 1.036 1.021 1.000 , 1.042 1.033 1.021 , 1.045 
15 0.935 0.920 , 0.949 0.983 0.967 , 1.000 1.015 0.995 , 1.036 0.980 0.969 , 0.991 
16 0.950 0.927 , 0.974 0.988 0.968 , 1.008 1.005 0.977 , 1.033 0.987 0.972 , 1.002 
17 0.978 0.957 , 0.999 1.003 0.984 , 1.023 1.027 1.001 , 1.053 1.015 1.001 , 1.029 
18 0.941 0.927 , 0.955 0.987 0.970 , 1.004 0.989 0.970 , 1.008 0.980 0.969 , 0.991 
19 0.960 0.942 , 0.978 1.000 0.982 , 1.019 1.000 0.978 , 1.023 1.000 0.988 , 1.013 
20 0.970 0.950 , 0.991 1.006 0.987 , 1.025 0.985 0.961 , 1.010 1.003 0.990 , 1.017 
21 0.941 0.921 , 0.961 0.989 0.970 , 1.008 1.005 0.980 , 1.030 0.984 0.971 , 0.997 
22 0.964 0.949 , 0.980 0.998 0.981 , 1.016 1.006 0.986 , 1.027 0.998 0.986 , 1.009 
23 0.987 0.969 , 1.004 1.012 0.994 , 1.030 1.012 0.990 , 1.034 1.019 1.007 , 1.031 
24 0.942 0.927 , 0.957 1.004 0.987 , 1.022 0.967 0.947 , 0.986 0.986 0.976 , 0.998 
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Supplementary Table 3: District level relative risks (RR) and 95% confidence intervals (CI) for a change from the minimum level of each climate variable 
to the maximum level.  
District 
Humidity Flooding Rainfall Temperature 
RR 95%CI RR 95%CI RR 95%CI RR 95%CI 
1 0.833 0.732, 0.935 0.921 0.827, 1.010 1.044 0.905, 1.183 0.942 0.862, 1.029 
2 0.851 0.744, 0.958 0.953 0.859, 1.047 1.120 0.981, 1.272 0.993 0.906, 1.080 
3 0.762 0.649, 0.875 0.958 0.864, 1.058 1.076 0.924, 1.228 0.949 0.862, 1.044 
4 0.631 0.530, 0.738 0.948 0.853, 1.042 0.987 0.848, 1.133 0.869 0.782, 0.964 
5 0.845 0.726, 0.964 1.021 0.916, 1.120 1.006 0.855, 1.164 1.058 0.956, 1.152 
6 1.071 0.958, 1.178 1.126 1.031, 1.225 0.930 0.791, 1.076 1.254 1.160, 1.349 
7 0.715 0.613, 0.810 1.031 0.937, 1.126 0.981 0.848, 1.120 0.978 0.891, 1.065 
8 1.190 1.095, 1.291 1.199 1.105, 1.293 0.886 0.760, 1.006 1.370 1.283, 1.457 
9 0.679 0.578, 0.786 1.016 0.921, 1.115 0.848 0.716, 0.994 0.935 0.848, 1.022 
10 0.798 0.685, 0.917 1.031 0.932, 1.131 0.975 0.823, 1.126 1.036 0.942, 1.138 
11 0.738 0.619, 0.857 0.990 0.890, 1.094 1.164 1.000, 1.322 1.007 0.906, 1.102 
12 0.762 0.673, 0.857 0.942 0.853, 1.031 1.038 0.912, 1.171 0.942 0.862, 1.022 
13 0.958 0.857, 1.059 1.178 1.079, 1.272 0.956 0.823, 1.088 1.247 1.160, 1.341 
14 1.024 0.929, 1.125 1.094 1.005, 1.189 1.133 1.000, 1.265 1.240 1.152, 1.327 
15 0.613 0.524, 0.697 0.911 0.827, 1.000 1.095 0.968, 1.228 0.855 0.775, 0.935 
16 0.703 0.566, 0.845 0.937 0.832, 1.042 1.032 0.855, 1.209 0.906 0.797, 1.015 
17 0.869 0.744, 0.994 1.016 0.916, 1.120 1.171 1.006, 1.335 1.109 1.007, 1.211 
18 0.649 0.566, 0.732 0.932 0.843, 1.021 0.930 0.810, 1.051 0.855 0.775, 0.935 
19 0.762 0.655, 0.869 1.000 0.906, 1.100 1.000 0.861, 1.145 1.000 0.913, 1.094 
20 0.822 0.703, 0.946 1.031 0.932, 1.131 0.905 0.754, 1.063 1.022 0.927, 1.123 
21 0.649 0.530, 0.768 0.942 0.843, 1.042 1.032 0.874, 1.190 0.884 0.789, 0.978 
22 0.786 0.697, 0.881 0.990 0.900, 1.084 1.038 0.912, 1.171 0.985 0.898, 1.065 
23 0.923 0.816, 1.024 1.063 0.969, 1.157 1.076 0.937, 1.215 1.138 1.051, 1.225 
24 0.655 0.566, 0.744 1.021 0.932, 1.115 0.791 0.665, 0.912 0.898 0.826, 0.985 
Minimum and maximum mean-normalized values (1) humidity: -2.7SD, 2.2SD (2) flooding: -2.0, 2.3 (3) rainfall: -0.9, 4.5 (4) temperature: -3.2, 3.1
76 
 
 
4.2 Supplementary Figures 
 
Supplementary Figure 1: Population growth by district over time. To account for changing 
population size over the period included in the analysis (2005-2010), we estimated weekly 
district-level population sizes using linear interpolation, assuming a constant rate of change in 
district population size between available census observations from 2005, 2008, 2009 and 2010 
(Statistical Yearbook of Ho Chi Minh City 2011, 2012). 
77 
 
 
Supplementary Figure 2: District level random intercept and change in reporting from 
2008-2010. (A) District level variability in baseline risk assumed to apply consistently over time, 
shown in relative risk in terms of deviation from overall average rate. (B) District level relative 
risk of reporting in any period after 2008, again shown in terms of deviation from overall average 
rate. Dashed lines in each panel are provided as a guide for assessing statistical significance. 
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Supplementary Figure 3: District level time series. Count of diarrheal cases per week over the 
study period (2005-2010) by district. 
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Supplementary Figure 4: District level weather and climate effects. Relative risks of flooding, 
humidity, rainfall and temperature by district predicted from the mixed effects model. The dashed 
line in each panel is provided as a guide for assessing statistical significance.  
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Supplementary Figure 5: Goodness of fit by district. Each panel illustrates the fit of the model 
to the data from each district using 1000 simulations from the fitted model. Points indicate the 
number of cases for each week. The solid line shows the median simulated value for each week, 
and the gray shaded area shows the range from the minimum to maximum simulated values.  
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Supplementary Figure 6: District level deviance residuals. Each panel of the plot shows the 
deviance residuals for each district after accounting for fixed effects, and seasonal and district-
level random effects.  
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Supplementary Figure 7: Partial autocorrelation function. Partial autocorrelation function 
(PACF) of district-level residuals. Points in each panel of the plot show the PACF for each district 
at each week of a 10-week lag. Dashed lines at 0.1 and -0.1 show a range of values indicating 
minimal residual temporal autocorrelation.  
83 
 
5 RESEARCH PAPER 3:  The epidemiology and aetiology of diarrhoeal 
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5.1 Appendix A 
Table: Rates of breastfeeding in all infants enrolled in Ho Chi Minh City by month of follow up visit, 2009-2013, n(%) 
Breastfed? 
Month of follow up 
1 2 3 4 6 9 12 Total 
Yes 
 
3675 (88.7) 3337 (81.7) 2941 (73.2) 2553 (63.5) 1610 (41.8) 1427 (36.9) 1230 (31.9) 16,773 
 
Yes, exclusively 1737 (41.9) 1429 (35) 1184 (29.5) 805 (20) 76 (2) 21 (0.5) 1 (0) 5,253 
 
Yes, plus formula 1938 (46.8) 1908 (46.7) 1750 (43.6) 1623 (40.4) 209 (5.4) 51 (1.3) 5 (0.1) 7,484 
 
Yes, plus form and food 0 (0) 0 (0) 4 (0.1) 73 (1.8) 909 (23.6) 1044 (27) 993 (25.8) 3,023 
 
Yes, plus food 0 (0) 0 (0) 3 (0.1) 52 (1.3) 416 (10.8) 311 (8) 231 (6) 1,013 
No 
 
467 (11.3) 749 (18.3) 1075 (26.8) 1468 (36.5) 2241 (58.2) 2445 (63.1) 2620 (68.1) 11065 
 
No, only formula 464 (11.2) 744 (18.2) 1063 (26.5) 1232 (30.6) 264 (6.9) 87 (2.2) 39 (1) 3,893 
 
No, food only 1 (0) 0 (0) 0 (0) 3 (0.1) 7 (0.2) 22 (0.6) 16 (0.4) 49 
 
No, food & form 2 (0) 4 (0.1) 8 (0.2) 138 (3.4) 1773 (46) 2269 (58.6) 2563 (66.6) 6,757 
 
Other 0 (0) 1 (0) 4 (0.1) 95 (2.4) 197 (5.1) 67 (1.7) 2 (0.1) 366 
Total 4142 (100) 4086 (100) 4016 (100) 4021 (100) 3851 (100) 3872 (100) 3850 (100) 27,838 
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6 RESEARCH PAPER 4:  The rising dominance of Shigella sonnei: An 
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6.1 Supplementary Information 
Table S1. Country-specific references for figure 1 showing the ratio of S. sonnei to S. 
flexneri isolated from 100 countries, 1990-2014. 
 Listed in alphabetical order by country. Missing countries did not have any publically 
available data >1990. 
Country Reference 
 
Argentina Rolfo F, Marin GH, Silberman M, Pattin J, Gatti B, et al. (2012) 
Epidemiological study of shigellosis in an urban area of Argentina. J 
Infect Dev Ctries 6: 324–328. 
 
Australia Australia’s Notifiable Disease Status, 2009: Annual Report of the 
National Notifiable Diseases Surveillance System (2009). Canberra, 
Australia. Available at 
http://www.health.gov.au/internet/main/publishing.nsf/ Content/cda-
pubs-annlrpt-nndssar.htm 
Austria 
 
Bundesministerium Fur Gesundheit: Mitteilungen fur das offentliche 
Gesundheitswesen (Public Health Newsletter), Ausgabe 3, Quartal 
2014 (2014). Wien, Austria. Available at 
http://bmg.gv.at/cms/home/attachments 
/0/2/1/CH1184/CMS1412325626202/nl_3_quartal_2014_neuerliche_a
ussendung_23102014.pdf 
Bahrain Jamsheer A, Bindayna K, Al-Balooshi N, Botta G (2003) Trend of 
antibiotic resistance in 1316 Shigella strains isolated in Bahrain. Saudi 
Med J 24: 424–426. 
Bangladesh Livio S, Strockbine NA, Panchalingam S, Tennant SM, Barry EM, et 
al. (2014) Shigella isolates from the global enteric multicenter study 
inform vaccine development. Clin Infect Dis 59: 933–941. 
Belgium Vrints M, Mairiaux E, Van Meervenne E, Collard J-M, Bertrand S 
(2009) Surveillance of antibiotic susceptibility patterns among Shigella 
sonnei strains isolated in Belgium during the 18-year period 1990 to 
2007. J Clin Microbiol 47: 1379–1385. 
Bhutan Ruekit S, Wangchuk S, Dorji T, Tshering KP, Pootong P, et al. (2014) 
Molecular characterization and PCR-based replicon typing of 
multidrug resistant Shigella sonnei isolates from an outbreak in 
Thimphu, Bhutan. BMC Res Notes 7: 95–104. 
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Bolivia Townes JM, Quick R, Gonzales OY, Linares M, Damiani E, et al. 
(1997) Etiology of Bloody Diarrhea in Bolivian Children: Implications 
for Empiric Therapy. J Infect Dis 175: 1527–1530. 
Botswana Rowe JS, Shah SS, Motlhagodi S, Bafana M, Tawanana E, et al. (2010) 
An epidemiologic review of enteropathogens in Gaborone, Botswana: 
shifting patterns of resistance in an HIV endemic region. PLoS One 5: 
e10924. 
Brazil Da Cruz CBN, de Souza MCS, Serra PT, Santos I, Balieiro A, et al. 
(2014) Virulence factors associated with pediatric shigellosis in 
Brazilian Amazon. Biomed Res Int 2014: 539697. 
Bulgaria Bratoeva MP, John JF, Barg NL (1992) Molecular Epidemiology of 
Trimethoprim-Resistant Shigella boydii Serotype 2 Strains from 
Bulgaria. J Clin Microbiol 30: 1428–1431. 
Burkina Faso Bonkoungou IJO, Haukka K, Österblad M, Hakanen AJ, Traoré AS, et 
al. (2013) Bacterial and viral etiology of childhood diarrhea in 
Ouagadougou, Burkina Faso. BMC Pediatr 13: 36–42. 
Cambodia Study: Meng CY, Smith BL, Bodhidatta L, Richard SA, Vansith K, et 
al. (2011) Etiology of Diarrhea in Young Children and Patterns of 
Antibiotic Resistance in Cambodia. Pediatr Infect Dis J 30: 331–335. 
 
Species data: Dr Ladaporn Bodhidatta, Armed Forces Research 
Institute of Medical Sciences, Bangkok, Thailand, Department of 
Enteric Diseases. 
 
Canada Canadian Integrated Surveillance Report: Salmonella, Campylobacter, 
verotoxigenic E. coli and Shigella, from 2000-2004 (2009). Available 
at http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/09vol35/35s3/index-
eng.php 
Central African 
Republic 
Bercion R, Njuimo SP, Boudjeka PM, Manirakiza A (2008) 
Distribution and antibiotic susceptibility of Shigella isolates in Bangui, 
Central African Republic. Trop Med Int Heal 13: 468–471. 
Chile Hamilton-West C, J VP, Carlos J, Hormazábal O, Z RL, et al. (2007) 
Epidemiología clínica y molecular de las infecciones por Shigella spp 
en ninos de la Region Metropolitana durante el verano 2004-2005. Rev 
Med Chil 135: 1388–1396. 
China Zhang J, Wang F, Jin H, Hu J, Yuan Z, et al. (2014) Laboratory 
monitoring of bacterial gastroenteric pathogens Salmonella and 
Shigella in Shanghai, China 2006-2012. Epidemiol Infect: 1–8. 
Colombia Urbina D, Arzuza O, Young G, Parra E, Castro R, et al. (2003) 
Rotavirus type A and other enteric pathogens in stool samples from 
children with acute diarrhea on the Colombian northern coast. Int 
Microbiol 6: 27–32. 
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Costa Rica Achi R, Mata L, Siles X, Lindberg A (1996) Immunomagnetic 
Separation and PCR Detection Show Shigellae to be Common Faecal 
Agents in Children From Urban Marginal Communities of Costa Rica. 
J Infect 32: 211–218. 
Côte d'Ivoire Antoine B, Adjehi D, Nathalie G, Valerie G, Etienne D, et al. (2010) 
Virulence Factors and Resistance Profile of Shigella Isolated During 
Infectious Diarrhea in Abidjan, Côte D’ Ivoire. J Appl Sci Res 6: 594–
599. 
Cuba Bravo LF, Correa Y, Clausell JF, Fernandez A, Ramírez M, et al. 
(2009) Caracterización de factores de virulencia y susceptibilidad 
antimicrobiana en cepas de Plesiomonas shigelloides aisladas de 
pacientes con diarrea aguda en Cuba. Microbiol Clin 26: 233–238. 
Denmark Berger S (2014) Shigellosis: Global Status - 2014 edition. Gideon 
Informatics. 
Djibouti Mikhail IA, Fox E, Haberberger L, Ahmed MH, Abbatte EA (1990) 
Epidemiology of Bacterial Pathogens Associated with Infectious 
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2004). Epidemiol Infect 134: 1237–1248. 
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Immunol Infect 39: 392–395. 
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Text S1. Methods for antimicrobial resistance and gene content data shown in 
Figure 2. A total of 136 Shigella flexneri and 231 Shigella sonnei isolates were collected 
between 1995 and 2010 as part of ongoing studies across Vietnam [1,2]. Antimicrobial 
susceptibilities were tested at the time of isolation by the modified Bauer-Kirby disk 
diffusion method, as recommended by the CLSI guidelines [3]. MICs were accessed by 
E-test, according to the manufacturer’s recommendations (AB Biodisk). Mueller-Hinton 
agar and antimicrobial discs were purchased from Unipath, Basingstoke, United 
Kingdom. Escherichia coli ATCC 25922 was used as the control strain. The inhibitory 
zone sizes were recorded and interpreted according to current CLSI breakpoint guidelines 
[3]. The following antimicrobials were used for Shigella.spp. susceptibility testing: 
ampicillin (AMP), chloramphenicol (CHL), ciprofloxacin (CIP), ceftriaxone (CRO), 
gatifloxacin (GAT), gentamicin (GEN), nalidixic acid (NAL), ofloxacin (OFX), 
trimethoprim/ sulfamethoxazole (SXT), tetracycline (TET) and trimethoprim (TMP). 
Additionally, the isolates were subjected to DNA extraction by using Wizard Genomic 
DNA Extraction Kit (Promega, Wisconsin, USA), and whole genome sequenced on an 
Illumina Hiseq2000 platform (Illumina, San Diego USA) to generate 150bp paired-end 
reads, as previously described [4].  De novo assemblies were generated for each read set 
using Velvet and VelvetOptimiser [5]. Contigs less than 100bp in size were excluded for 
further analysis. The short-read sequence data were deposited in the European Read 
Archive under the accession number ERP000182, ERP000631 and ERP000631. The 
resistance gene profiles and content (resistome) of each isolate were characterised using a 
manually curated database, based on the ResFinder database [6]. Each gene in the 
database was mapped against the isolate assemblies to identify complete genes. Where 
fragments matching the 5´or 3´ ends of resistance genes were identified at contig 
boundaries, sequencing reads were mapped to all matching candidate genes and their 
120 
 
presence assessed based on mapping coverage across the gene. 
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Abstract 
Background: Diarrhoeal disease remains a significant cause of childhood morbidity and 
mortality globally. Shigella spp. are a genus of Gram-negative bacteria that cause bloody/mucoid 
diarrhoea with potentially severe consequences in young children. Antimicrobial resistance is a 
growing threat, and little is known about Shigella or other agents of diarrhoeal disease in the 
community. 
Methods: Children between the ages of 12-36 months were enrolled into a large community 
cohort with active surveillance for diarrhoeal disease in Ho Chi Minh City, Vietnam. Clinical 
samples were collected at routine follow up visits and during diarrhoeal disease episodes. A 
multiplex molecular diagnostic platform was used to identify >15 pathogens with high sensitivity 
and specificity.  
Results: For the first year of the cohort, a total of 748 children were enrolled and the incidence of 
diarrhoeal disease was 70 episodes/100 child years of observation (CYO). Norovirus was most 
common (13 episodes/100CYO) followed by Salmonella (9 episodes/100CYO). The incidence of 
Shigella was 1.5/100CYO and was similar in both two and three year olds. Malnourished children 
in the cohort were significantly more at risk of developing a Shigella infection.  
Conclusions: Diarrhoeal disease in the community in Ho Chi Minh City is most frequently 
caused by norovirus in both two and three year olds. Shigella infections still plague the 
malnourished. The community cohort structure of this study will permit a wide range of future 
analyses ranging from immunology to host genetics to better understand Shigella and diarrhoeal 
disease as a whole.   
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Introduction 
Diarrhoea remains a substantial cause of morbidity and mortality amongst children globally [1,2]. 
Shigella, a major cause of bacillary dysentery, is a considerable public health problem in many 
regions, particularly in the second and third year of life [2,3]. Infections in young children can 
result in severe acute illness as well as significant reductions in linear growth during childhood 
[3–5]. Of the four species of Shigella, S. sonnei is emerging in many regions traditionally 
dominated by S. flexneri that are undergoing economic industrialisation [6]. Reasons behind this 
emergence are unclear [7], yet due to alarming levels of antimicrobial resistance against first and 
second line therapies [8–11], S. sonnei is now a formidable threat in areas such as Asia, Latin 
America and the Middle East [12–17]. Although vaccines are under development, a safe and 
effective candidate has yet to be licensed [18].   
Vietnam is a lower middle income country with a rapidly industrialising population of 90 million 
people and dual burdens of both infectious and non-communicable diseases [19]. Ho Chi Minh 
City (HCMC), located in the tropical south, is the largest city in Vietnam and has a considerable 
burden of diarrhoeal disease [20–22]. Although paediatric Shigella, rotavirus and norovirus 
patients are known present commonly to hospitals in this setting [21], little is known about the 
true burden of disease in the community. A study conducted in 2001-2003 in the central, coastal 
province of Khanh Hoa in Vietnam found the incidence of diarrhoea and Shigella in children aged 
under five years to be 11.5/100 and 4.9/1000 per year, respectively [23].  
More recently, a birth cohort in southern Vietnam quantified the incidence of diarrhoeal disease in 
infants <12 months of age to be 271/1000 infant years of observation (IYO), with significant 
differences between HCMC (89/1000 IYO) and the rural Dong Thap province (604/1000 IYO), 
located in the Mekong Delta [24]. Both of these studies relied on passive, clinic-based diarrhoeal 
disease detection, so likely represent underestimates of the true burden of both diarrhoea generally 
and Shigella specifically.  Therefore, we conducted a longitudinal, community-based cohort using 
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active surveillance for diarrhoeal disease to more accurately estimate the burden of Shigella and 
other diarrhoeal infections in this setting [25].   
Due to known high levels of antimicrobial usage in the community in Vietnam [26,27], we 
detected an array of diarrhoeal pathogens using both traditional microbiological methodology in 
addition to molecular techniques to increase our sensitivity of detection during a diarrhoeal 
episode. Molecular diagnostic technology such as the Luminex xTAG Gastrointestinal Pathogen 
Panel system dramatically expands the ability to diagnose a large variety of viral, bacterial and 
parasitic infections in a period of hours [28].  Luminex relies on molecular amplification of 
specific regions of the genome of a variety of pathogens, which are then hybridised to pathogen-
specific beads for detection and quantification by fluorescence. With the ability to identify up to 
21 different enteric pathogens and with sensitivity and specificity exceeding 90% for a majority of 
targets in the Vietnamese setting (Duong et al, manuscript in preparation), this system has been 
also shown to be effective in a variety of high-income settings [29–31] and provides an 
unprecedented level of diagnostic scope and sensitivity. 
The overall aim of this study was to describe the epidemiology of Shigella infections in HCMC to 
inform the development and potential introduction of Shigella vaccines. We report age-specific 
incidence of Shigella and other diarrhoeal pathogens using molecular diagnostics from the first 
year of a cohort study employing active surveillance for diarrhoeal disease in the community.  
Furthermore, we examine clinical manifestations, rates of coinfection, seasonality and risk factors 
of various pathogens to develop a better understanding of diarrhoeal disease occurring in the 
community an industrialising country in Southeast Asia.  
Methods 
Cohort design 
The protocol for this diarrhoea cohort has been published previously [25]. Briefly, 748 children 
between the ages of 12-36 months were enrolled in a community cohort based in district 8 of 
HCMC. Children were identified for screening if they had participated in a previous birth cohort 
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[32], which enrolled pregnant mothers at Hung Vuong Hospital who lived in district 8 of HCMC. 
In this original birth cohort, children were followed up for one year with regular health checkups 
and passive disease surveillance [24]. When children finished the original birth cohort at 12 
months of age they were eligible for enrolment into the diarrhoea cohort with active disease 
surveillance. Once enrolled, these children were followed up for two years with routine health 
checkups every six months. At routine follow up visits, a rectal swab, nasopharyngeal swab and 
small blood sample were collected, along with information regarding growth metrics and any 
unrecorded hospitalisations in the interim period. For the active surveillance component, an SMS 
was sent to each participant biweekly enquiring as to whether the study child had experienced 
diarrhoea in the last seven days. For those who did not reply, phone calls were made to 
established presence of diarrhoea in the preceding seven days. Diarrhoea was defined as three or 
more loose stools in a period of 24 hours or one stool of bloody or mucoid diarrhoea (dysentery) 
[33]. If diarrhoea was reported, a study nurse went to the participant’s home or the family was 
invited to attend the Hospital for Tropical Disease for examination. When ill, a stool sample was 
collected and a clinical case report form administered.  
Clinical specimen collection and traditional microbiology 
Stool samples were collected in a sterile pot and transported within 24 hours of collection. 
Classical microbiological culturing was performed on all collected fresh stool samples on the day 
of sampling to isolate common diarrheal bacteria including Shigella spp., Salmonella spp., 
Campylobacter spp.,  Plesiomonas spp. and Aeromonas spp. as described previously [34]. 
Specific serotypes of Shigella spp. and Salmonella spp. were identified by slide agglutination with 
antigen grouping sera and monovalent antisera, and Campylobacter jejuni was differentiated from 
Campylobacter coli by the hippurate hydrolysis test as previously described [34]. A fresh smear 
of faecal specimen was prepared in phosphate buffered saline to examine the presence of Giardia 
lamblia, Entamoeba histolytica, and Cryptosporidium cysts [34].  
Nucleic acid extraction, multiplex PCR and Luminex procedures 
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A total of 200µl of each stool specimen was used for nucleic acid extraction with 10µl xTAG 
MS2 (internal control) by MagNA Pure-96 machine (Roche) according to the manufacturer’s 
instruction. Each 15µl-master mixture contained 7.5µl of 5X xTAG One Step Buffer, 2.5µl of 
xTAG GPP Primer Mix, 0.5µl of xTAG BSA (10mg/ml), 2µl of xTAG One Step Enzyme Mix, 
and water up to 15µl. A total of 10µl of the appropriate extracted nucleic acid sample was used as 
template for the PCR step. The PCR reaction was performed at 53°C for 20 minutes and the 
thermal cycler conditions used were enzyme activated at 95°C for 15 min; 95°C for 30s; 38 cycles 
of 95°C for 30s, 58°C for 30s, and 72°C for 30s; a final extension at 72°C for 2 min; and holding 
at 4°C. 
The xTAG GPP Bead mix and Reporter Buffer containing 0.15M NaCl were thawed and the 0.22 
SAPE was diluted 75-fold with the xTAG Reporter Buffer and kept away from light until use. 
Each reaction contained 20µl xTAG Bead Mix, 5µl PCR product and 75µl of reporter solution. 
The hybridisation was performed at 60
0
C for 3 min, 45
0
C for 45 min, and holding at 45
0
C. When 
the hybridisation was complete, the plate was placed on the Luminex plate heater block and read 
by Luminex
®
 100/200
TM
 software. 
Statistical analyses 
A new episode of diarrhoea was defined by ≥7 days between the onset dates of symptoms. 
Incidence was calculated by dividing the number of distinct episodes by individual child follow 
up time and reported as a population mean with 95% confidence intervals (CIs). Univariate 
logistic regression was performed to examine pathogen-specific risk factors. Cases included any 
individual who had at least one recorded pathogen-specific diarrhoeal episodes diagnosed by the 
Luminex assay and controls included the remaining children in the cohort, whether diarrhoea-
positive for another pathogen or diarrhoea-negative throughout the study period. Longitudinal 
prevalence was estimated by using the number of positive SMS/calling responses divided by the 
total number of weeks under observation. As the SMS asked explicitly about diarrhoea in the last 
7 days, one SMS equated to one week under observation. Analyses were performed in STATA 
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v13.1 (College Station, TX, USA) and plots were generated in R (R Statistical Foundation for 
Computing, Vienna, Austria; https://cran.r-project.org/) using the ggplot2 package [35]. 
Ethical approval 
The Hospital for Tropical Diseases and Hung Vuong obstetric hospital participated in the study. 
The protocol was approved by the institutional review boards of these hospitals as well as the 
Oxford Tropical Research Ethics Committee (OxTREC approval: 0209) and the London School 
of Hygiene & Tropical Medicine (Ref: 8632). Written informed consent was obtained from all 
participants.  
Results 
Baseline 
From June 2014 – July 2015 there were 748 children aged 12-36 months who were enrolled into 
the diarrhoea cohort. The median age of children at enrolment was 24 months (interquartile range 
[IQR]: 13-30 months), with 53% (398/748) male as shown in Table 1. At least 42% (314) of 
children reported at least one dose of a rotavirus vaccine, the first dose of which was at a median 
of two months of age (IQR: 2-3). The median time of follow up in the cohort in the first year was 
271 days (range: 137-365) and 15 children (2%) dropped out or were lost to follow up. The most 
common reason for dropping out was dislike of blood collection (10/15, 67%). There were no 
major socioeconomic differences between those that dropped out (2%) and those that remained in 
the cohort within the first year of enrolment and follow up (data not shown). A total of 244 (33%) 
children had at least one home or hospital visit or self-reported hospitalisation for diarrhoea and 
149 (20%) had at least one stool sample collected during a diarrhoeal episode throughout follow 
up.  
Incidence and longitudinal prevalence of diarrhoeal episodes 
During the first 12 months of the cohort study, there were 400 reported diarrhoeal episodes: 227 
(57%) were home visits, 166 (42%) were hospital visits at the HTD and 6 (2%) were self-reported 
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hospitalisations for diarrhoea at a hospital other than HTD. Stool was more often collected at 
HTD hospital visits (163/166, 98%) compared to during home visits (71/227, 31%) as many home 
visits were recorded only after the seven day window of a dirrhoeal episode. Only 12 (4.8%) 
episodes were home visits that went on to be hospitalised. There were a total of 558.9 child years 
of follow up recorded, leading to an overall incidence of 69.6 (95%CI: 59.2-80.0) diarrhoeal 
episodes per 100 child years of observation (CYO). Diarrhoeal episodes treated at home had an 
incidence of 40.5 (95%CI: 34.4-46.5) per 100 CYO and those treated in hospital 27.6 (95%CI: 
20.1-35.1) per 100 CYO.  
Over the 12 months of follow up, there were 12,636 SMS sent biweekly to participants (median 
18 SMS/participant, range: 4 – 23), with an SMS response rate of 35%. From the SMS and 
calling, there were 292 diarrhoeal episodes reported. The longitudinal period prevalence of 
diarrhoeal disease is therefore estimated to be 2.7% (95%CI: 2.2-3.1%), indicating that a child in 
this cohort will report diarrhoea on 1.4 (95%CI: 1.2-1.6) weeks in a one year period.   
Pathogen and age-specific incidence 
Using the Luminex platform, a variety of pathogens were identified in diarrhoeal stool samples as 
shown in Table 2. Diarrhoeal disease due to norovirus was most frequent (12.5 episodes [95%CI: 
8.4-16.5] per 100 CYO), followed by Salmonella spp. (8.8 episodes [95%CI: 5.8-11.9] per 100 
CYO) and C. difficile (7.4 episodes [95%CI: 4.8-9.9] per 100 CYO). The incidence of Shigella 
spp. as 1.5 episodes (95%CI: 0.5-2.6) per 100 CYO. The burden of disease detected through 
traditional microbiological culture methods was markedly reduced compared to the Luminex 
platform (Table 2). By age, children 12-23 months had the highest incidence of diarrhoeal disease 
generally (80.8 episodes [95%CI: 63.9-97.7] per 100 CYO) and similar burdens of both 
hospitalised (38.5 episodes [95%CI: 25.6 – 51.3] per 100 CYO) and home-treated (40.8 episodes 
[95%CI: 32.2-49.3] per 100 CYO) diarrhoeal disease. However, by the time children were ≥36 
months, home-treated diarrhoeal disease (19.3 episodes [95%CI: 8-30.5] per 100 CYO) were 
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much more frequent than hospitalised diarrhoeal disease (8.8 episodes [95%CI: 2.5-15.1] per 100 
CYO).  
The distribution of pathogens across age groups was interesting for several reasons (Table 3, 
Figure 1). First, norovirus was the most commonly identified aetiology in both two and three year 
old children, found in 22% (54/258) and 18% (22/121) of diarrhoeal stool samples, respectively. 
Secondly, C. difficile had an incidence of 12 episodes (95%CI: 7.6-16.5) per 100 CYO in two 
year olds, yet was rarely identified in older children. While the incidence of most pathogens 
declined between the second and third years of life, the incidence of Shigella, though low overall, 
was similar in both two (1.5 episodes per 100 CYO) and three year olds (2.1 episodes per 100 
CYO).  
Coinfection 
Of all 304 stool samples, a pathogen was detected in 223 (73%). A coinfection (>1 pathogen) was 
identified in 41% of stool samples with a detected pathogen (91/223). Coinfections were more 
common in diarrhoeal samples collected during home-treated diarrhoea (32/54, 59%) compared to 
hospitalised cases (52/129, 43%) (p=0.042, chi square test). The most common coinfection 
phenotype was norovirus/Salmonella (11%; 10/91) followed by norovirus/C. difficile (7%; 6/91) 
and norovirus/ETEC (7%; 6/91). As shown in Figure 2, Cryptosporidium (11 coinfections/11 
positive samples, 100%), ETEC (26/32, 81%), Salmonella spp. (41/56, 72%) and adenovirus 
(25/35, 71%) were commonly isolated in coinfections. Rotavirus (12 coinfection/32 positive 
samples, 38%), Shigella (4/10, 40%), Campylobacter (12/27, 44%) were least likely to be 
detected amongst a coinfection. Rates of coinfection were not different between age groups (data 
not shown).  
Reinfection 
Multiple episodes of the same pathogen in a single participant were most frequent with norovirus 
(8/56 patients, 14%), adenovirus (3/25 patients, 12%), C. difficile (4/36 patients, 11%) and 
Salmonella spp. (4/44 patients, 9%)  with median gaps between episodes of 19 days (IQR: 10-63), 
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39 days (IQR: 11-51), 66 days (51-122) and 51 days (34-88), respectively. The median number of 
episodes per patient for these four pathogens was 2-2.5, with a range of 2-7 episodes/patient for 
both norovirus and Salmonella spp., 2-4 episodes/patient for adenovirus and 2-3 episodes/patient 
for C. difficile. None of the patients infected with Shigella had multiple episodes (0/9).  
Seasonality 
As shown in Figure 3, several pathogens displayed an element of seasonality. Norovirus, for 
example, had a very sharp peak in incidence from August-October 2014, ranging from 23-40 
episodes/100 CYO. The overall count of norovirus cases, however, remained consistently high 
from August 2014 – March 2015, with a median episode count of 8.5 (IQR: 7-9.3) per month. 
Salmonella episodes also displayed strong seasonality in early autumn 2014, with incidence 
peaking at 44 episodes/100 CYO in August 2014. Finally, the incidence of C. difficile peaked 
August –November 2014, ranging from 12-25 episodes/100 CYO with a median episode count of 
6 episodes (IQR: 5.3-7.3) per month. 
Clinical manifestations  
Overall, 12% (20/165) of hospitalised and 0.4% (1/227) of home-treated diarrhoeal episodes had 
evidence of blood in the stool. A further 61% (100/165) of hospitalised and 17% (38/227) of 
home-treated episodes had mucoid diarrhoea. Over half (59%; 97/167) of diarrhoeal episodes 
treated in hospital were prescribed an antimicrobial. Macrolides were most commonly prescribed 
in hospital (34/87, 39%), followed by fluoroquinolones (24/87, 28%). For diarrhoeal illness at 
home, parents reported self-prescribed antimicrobial use in 25% of episodes (56/226) and 
probiotic use in 53% (119/226). Furthermore, 7% (16/227) of diarrhoeal episodes seen at home 
had a concomitant case of diarrhoea in the household, with the median age of the additional cases 
23 years (IQR: 2-44).  As shown in Table 4, Shigella monoinfections commonly presented with 
mucus or blood in the stool, abdominal pain and had the highest median axillary temperature on 
entry (38.5°C) compared to other diagnosed aetiologies. Additionally, viral infections tended to 
present with vomiting more frequently than bacterial infections.  
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Risks for pathogen-specific infections 
Basic univariate analyses demonstrated several risk factors for pathogen-specific diarrhoea. As 
shown in Tables 1 and 5, low weight and height for age Z-scores at 12 months of age were 
significant risks for Shigella infection. Younger children were significantly more likely to present 
with C. difficile, Salmonella spp. and norovirus. Male sex was also a significant risk for C. 
difficile, norovirus and rotavirus infections. Additionally, using the floor for defecation instead of 
a flush toilet was a significant risk for Salmonella spp. and adenovirus infections, whilst wearing 
a diaper was associated with Salmonella spp. and norovirus infections after controlling for age. 
Finally, regular consumption of probiotics was a significant risk factor for rotavirus infections.  
Discussion 
Diarrhoeal disease continues to persist as a significant cause of childhood morbidity globally [36]. 
Through a longitudinal community cohort in HCMC we have quantified the incidence of 
diarrhoea disease in children between 12-48 months to be 70 episodes/100 CYO and document a 
range of aetiologies present in the stool of ill children. Our overall incidence estimate is much 
higher than that found in the coastal city of Nha Trang (11.5/100 CYO) in children under 5 in the 
mid-2000’s [23]. This is likely due to differing strategies for diarrhoeal episode capture. Indeed, 
the rate of home-treated diarrhoeal episodes was almost 1.5 times as great as the rate of episodes 
treated at hospital, demonstrating that accurately quantifying diarrhoeal incidence in the 
community requires active surveillance. Yet our estimate is lower than that of Isenbarger et al, 
who found an incidence in Hanoi of 1.3 episodes/child/year in the late 1990s in children under 
five years of age [37], which likely reflects a true trend in declining morbidity due to diarrhoeal 
diseases in Vietnam over time as the country industrialises.  
Although the incidence of Shigella (1.5 episodes/100 CYO) was low in comparison other 
diarrhoeal aetiologies identified in the current cohort study, our Shigella incidence estimate is 
three times of that of a large study conducted a decade ago in central Vietnam and is in fact most 
similar to that of Indonesia (1.9/100/year), Pakistan (1.7/100/year) and China (1.9/100/year) from 
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the same study [23]. As the median age of children currently in the cohort was 24 months, half of 
our cohort has yet to progress through the age where Shigella infections are known to be more 
common (2-3 years) [2,3,21], suggesting that our incidence estimate will likely grow as the cohort 
matures. However, even with the limited number of Shigella episodes identified in the first year, 
children with Shigella were significantly more likely to be stunted at 12 months of age and 
presented very frequently with dysentery (blood and/or mucus in stool), demonstrating the 
relative severity and continuing burden of this bacterial infection in malnourished children [38].  
The use of the Luminex platform allows for a high level of diagnostic granularity with high 
sensitivity and specificity in a period of hours [29,39,40]. Through this assay we identified a large 
range of pathogens in the stool of children with diarrhoea, including most commonly norovirus, 
C. difficile, rotavirus, adenovirus and ETEC in the second year of life and norovirus, adenovirus, 
ETEC, Campylobacter spp. and Shigella spp. in the third year of life, similar to the GEMS and 
MAL-ED studies [2,3]. Yet, unlike the GEMS, we did not identify a particularly high incidence of 
Cryptosporidium (1.7 episodes/100 CYO), though this may be due to limited follow up time in 
our cohort. Furthermore, the ability to identify the aetiologies present in coinfection in addition to 
future work examining healthy stools of our cohort children will allow us to investigate the 
relative pathogenicity of each aetiology. In previous hospital-based studies in HCMC we 
identified Salmonella and Campylobacter spp. in the stools of asymptomatic controls under five 
years of age [21]. 
Though the number of diagnosed diarrhoeal episodes was relatively limited, we were still able to 
identify several risk factors with tangible preventative solutions, such as floor defecation in the 
instance of Salmonella and adenovirus, or the use of diapers again in Salmonella and norovirus 
infections. Encouraging the use of chamber pots for small children and likely proper hand hygiene 
when handling soiled diapers may prevent transmission of such pathogens within the home. More 
thorough analyses are warranted. Additionally, we found that rotavirus vaccination did not 
effectively prevent rotavirus disease in these cohort children and furthermore that probiotic 
consumption on a regular basis was actually a significant risk for rotavirus diarrhoea. Whether 
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such an association represents an interaction between probiotics and gut microbiota that would 
render a child more susceptible to rotavirus infection merits further study.  
One of the limitations of the present study was the frequency of follow up. We chose biweekly 
follow up as a compromise between impacting the behaviour of the participants, time availability 
of the study nurses and annoying the participants to the point where they drop out [41]. 
Furthermore, it has been shown that frequently surveying for diarrhoeal disease actually leads to 
reduced incidence of reporting [42]. Even with biweekly surveillance, we found a drop in the 
overall reporting of diarrhoea over time which may have led to underestimated rates of diarrhoeal 
disease. While our loss to follow up rate was low (2%), we acknowledge that we were unlikely to 
obtain information on all episodes of diarrhoea that occurred in our cohort. While our active 
surveillance strategy was able to capture substantially more episodes than passive surveillance 
[24], it will be important to evaluate the seroepidemiology of our cohort members to investigate 
seroconversion rates [43], which may provide a more accurate burden estimate. 
The rich dataset of this cohort study will permit a number of future analyses, including evaluation 
of the relative pathogenicity of the variety of identified aetiologies through examination of 
healthy stool samples as was done recently in the MAL-ED study [3]. We also aim to investigate 
the longitudinal immune response to a variety of aetiologies in addition to the development of an 
antigen array designed to identify immunogenic proteins for Shigella spp. [44]. Furthermore, we 
will perform a more rigorous analysis of risk factors, including a geospatial analysis [45], upon 
the completion of the cohort. Finally we will use clinical samples collected through this cohort to 
explore the relationship between genetic variation and disease susceptibility through genetic 
association, candidate gene and genome wide-association studies in the future [25].  
In conclusion, through the structure of a large, longitudinal community-based cohort study we 
show the incidence of diarrhoeal disease in children between 12-48 months of age to be 70 
episodes/100 CYO and highlight the diversity of pathogens identified in stool of sick children. 
Norovirus and Salmonella predominated in all age groups, and Shigella infections were found 
frequently in malnourished children. Future work on samples and data collected from this cohort 
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will be invaluable in providing a more detailed evaluation of pathogenicity, seroconversion and 
immune response to a variety of important pathogens causing diarrhoea in this urbanising, 
industrialising setting in Southeast Asia.  
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Table 1: Baseline characteristics of cohort members stratified by diarrhoeal pathogen, n(%) or median(interquartile range) as appropriate 
Characteristic 
C. difficile Campy Salmonella Shigella Adenovirus Norovirus Rotavirus Total 
n=36 n=24 n=44 n=9 n=25 n=56 n=28 n=748 
Median age in months 15.3 (14-19) 22.7 (16-28) 18.4 (15-24) 22.3 (18-31) 21.1 (17-25) 18.6 (15-25) 18.9 (17-22) 24.3 (12.6-30.4) 
Male sex 27 (75.0%) 14 (58.3%) 28 (63.6%) 6 (66.7%) 14 (56%) 40 (71.4%) 20 (71.4%) 398 (53.2%) 
Growth metrics at 12m
†
 
       
 
Weight for age -0.08 (-0.7-0.7) -0.13 (-0.5-0.6) -0.05 (-0.6-0.7) -0.33 (-0.5-0.3) 0.02 (-0.6-0.5) 0.08 (-0.4-0.6) -0.05 (-0.7-0.8) 0.21 (-0.5 - 1.1) 
 
Height for age 0.50 (-0.3-1.1) 0.01 (0.6-0.7) 0.31 (-0.3-0.8) 0.14 (0-0.9) 0.34 (-0.3-0.8) 0.38 (-0.4-0.7) 0.13 (-1.5) -0.11 (-0.8 - 0.5) 
 
Weight for height -0.10 (-0.7-0.4) 0 (-0.5-0.3) 0.10 (-0.6-0.3) 0.10 (-0.6-0) -0.09 (-0.7-0.4) -0.10 (-0.5-0.5) 0 (-0.7-0.8) 0.39 (-0.38 - 1.2) 
Maternal education
‡
 
       
 
Lower secondary  17 (47.2%) 10 (41.7%) 23 (52.3%) 5 (55.6%) 12 (48.0%) 35 (62.5%) 19 (67.9%) 394 (52.7%) 
 
Higher secondary 19 (52.8%) 14 (58.3%) 21 (47.7%) 4 (44.4%) 13 (52.0%) 21 (37.5%) 9 (32.1%) 354 (47.3%) 
Rotavirus vaccine 
        
 
1 dose 17 (47.2%) 9 (37.5%) 16 (36.4%) 4 (44.4%) 6 (24.0%) 25 (44.6%) 9 (32.1%) 314 (42.0%) 
 
2 doses 15 (41.7%) 9 (37.5%) 16 (36.4%) 4 (44.4%) 6 (24.0%) 23 (41.1%) 9 (32.1%) 304 (40.6%) 
Drinking water^ 
        
 
Piped to home 24 (66.7%) 15 (62.5%) 28 (63.6%) 6 (66.7%) 14 (56.0%) 35 (62.5%) 16 (57.1%) 487 (65.1%) 
 
Bottled 12 (33.3%) 9 (37.5%) 16 (36.4%) 3 (33.3%) 11 (44.0%) 20 (35.7%) 12 (42.9%) 255 (34.1%) 
Toilet 
        
 
Toilet 6 (24.0%) 4 (23.5%) 4 (13.8%) 2 (28.6%) 4 (21.1%) 7 (17.1%) 6 (31.6%) 171 (26.7%) 
 
Chamber pot 14 (56.0%) 10 (58.8%) 17 (58.6%) 3 (42.9%) 10 (52.6%) 28 (68.3%) 9 (47.4%) 400 (62.5%) 
 
Floor 2 (8.0%) 2 (11.8%) 5 (17.2%) 2 (28.6%) 5 (26.3%) 3 (7.3%) 2 (10.5%) 55 (8.6%) 
 
Other 3 (12.0%) 1 (5.9%) 3 (10.3%) 0 (0%) 0 (0%) 3 (7.3%) 2 (10.5%) 14 (1.9%) 
Diaper 13 (36.1%) 8 (33.3%) 23 (52.3%) 3 (33.3%) 6 (24.0%) 22 (39.3%) 9 (32.1%) 126 (16.8%) 
Household crowding* 22 (61.1%) 15 (62.5%) 30 (68.2%) 5 (55.6%) 12 (48.0%) 33 (58.9%) 15 (53.6%) 450 (60.6%) 
Regular probiotics 11 (30.6%) 9 (37.5%) 20 (45.5%) 4 (44.4%) 12 (48.0%) 24 (42.9%) 16 (57.1%) 259 (34.6%) 
† WHO Z-scores at 12 months of age; ‡ Lower secondary or below, higher secondary or above; ^One additional category “Other” for drinking water (not 
shown), Norovirus: 1 (1.8%) and Total: 6 (0.8%); *>2 people/room 
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Table 2: Count and incidence per 100 child years of follow up of pathogen specific diarrhoeal 
episodes diagnosed by either microbiological culture or the Luminex Gastrointestinal Pathogen 
Panel 
Pathogen 
Culture confirmed Luminex 
n Incidence (95%CI) n Incidence (95%CI) 
C. difficile 
  
42 7.4 (4.8-9.9) 
Campylobacter 16 2.6 (1.3-3.9) 24 4.1 (2.5-5.8) 
E. coli O157 
  
5 1.0 (0.1-1.9) 
ETEC 
  
28 4.5 (2.6-6.4) 
Salmonella 9 1.51 (0.4-2.7) 54 8.8 (5.8-11.9) 
Shigella 2 0.37 (0-0.9) 9 1.5 (0.5-2.6) 
STEC 
  
2 0.3 (0-0.7) 
V. cholerae 
  
0 0 (0) 
Yersinia  
  
0 0 (0) 
Adenovirus 
  
30 5.1 (2.9-7.3) 
Norovirus 
  
76 12.5 (8.4-16.5) 
Rotavirus 
  
29 4.8 (3.0-6.5) 
Cryptosporidium 1 0.2 (0-0.5) 11 1.7 (0.7-2.8) 
Giardia 0 0 3 0.4 (0-0.9) 
E. histolytica 1 0.2 (0-0.7) 2 0.3 (0-0.8) 
CI: confidence interval 
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Table 3: Number of episodes and incidence of diarrhoea per 100 child years by age group 
Episodes 
12-23 month 24-35 month >=36 month 
n Incidence (95%CI) n Incidence (95%CI) n Incidence (95%CI) 
Total 247 80.8 (63.9-97.7) 122 59.9 (32.8-87.0) 31 28.1 (15.2-41.0) 
Home 122 40.8 (32.3-49.3) 83 29.4 (20.8-38.1) 22 19.3 (8.0-30.5) 
Hospital 120 38.5 (25.6-51.3) 37 30.1 (4.3-55.9) 9 8.8 (2.5-15.1) 
Luminex detection       
 
C. difficile 37 12.0 (7.6-16.5) 4 1.3 (0-2.6) 1 0.6 (0-1.8) 
 
Campylobacter 14 4.2 (2.0-6.4) 6 14.1 (0-37.9) 4 3.1 (0-6.3) 
 
E. coli O157 3 1.2 (0-2.5) 2 1.3 (0-3.5) 0 0 (0) 
 
ETEC 19 5.8 (2.9-8.8) 7 3.3 (0.2-6.4) 2 2.0 (0-4.9) 
 
Salmonella 40 13.0 (7.8-18.1) 14 17.9 (0-42.1) 0 0 (0) 
 
Shigella 5 1.5 (0.2-2.8) 4 2.1 (0-4.5) 0 0 (0) 
 
STEC 2 0.6 (0-1.4) 0 0 (0) 0 0 (0) 
 
Adenovirus 19 6.2 (3.2-9.3) 9 5.4 (0.5-10.3) 2 2.6 (0-6.5) 
 
Norovirus 54 16.7 (10.1-23.4) 22 9.0 (3.7-14.3) 0 0 (0) 
 
Rotavirus 24 7.8 (4.5-11.0) 4 1.2 (0-2.4) 1 1.3 (0-3.7) 
 
Cryptosporidium 9 3.1 (0.9-5.2) 2 0.6 (0-1.5) 0 0 (0) 
 
Giardia 2 0.5 (0-1.2) 1 0.2 (0-0.6) 0 0 (0) 
 
E. histolytica 0 0 (0) 2 0.6 (0-1.5) 0 0 (0) 
CI: confidence interval
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Table  4: Clinical characteristics of pathogen-specific monoinfections and broad classification of coinfection (bacterial, viral or bacterial/viral), n(%) or 
median (interquartile range) as appropriate 
Characteristic 
Monoinfection Coinfection 
C. difficile Campylobacter Salmonella Shigella Adenovirus Norovirus Rotavirus Bacterial Viral Bac/Viral 
n=10 n=7 n=9 n=5 n=5 n=24 n=9 n=8 n=7 n=31 
Type of diarrhoea 
          
 
Watery 7 (77.8%) 5 (71.4%) 7 (77.8%) 3 (60.0%) 5 (100%) 20 (83.3%) 9 (100%) 2 (25.0%) 6 (85.7%) 29 (93.5%) 
 
Mucoid 4 (44.4%) 3 (42.9%) 5 (55.6%) 4 (80.0%) 2 (40.0%) 10 (41.7%) 3 (33.3%) 7 (87.5%) 5 (71.4%) 21 (67.7%) 
 
Bloody 1 (11.1%) 2 (28.6%) 1 (11.1%) 1 (20.0%) 0 (0%) 1 (4.2%) 0 (0%) 2 (25.0%) 1 (14.3%) 2 (6.5%) 
No episodes/24 hr 5 (3-6) 6 (2-10) 6 (5-8) 6 (6-10) 3 (3-7) 5 (4-7.5) 5 (4-8) 5.5 (5-6) 4 (3-4) 5 (4-7) 
Temperature 37 (37-37) 37 (37-37.3) 37 (37-37.8) 38.5 (37.5-38.5) 37 (37-37) 37 (37-37) 38 (37-38) 37.3 (37-38) 38 (37-39.2) 37 (37-37.6) 
Symptoms 
          
 
Vomit 5 (55.6%) 3 (42.9%) 5 (55.6%) 2 (40.0%) 2 (40.0%) 16 (66.7%) 7 (77.8%) 5 (62.5%) 5 (71.4%) 17 (54.8%) 
 
Abdominal pain 3 (33.3%) 1 (14.3%) 3 (33.3%) 4 (80.0%) 3 (60.0%) 9 (37.5%) 1 (11.1%) 2 (25.0%) 3 (42.9%) 7 (22.6%) 
Therapies 
          
 
Antimicrobials 2 (22.2%) 4 (57.1%) 6 (66.7%) 4 (80.0%) 2 (40.0%) 13 (54.2%) 4 (44.4%) 6 (75.0%) 6 (85.7%) 18 (58.1%) 
 
Rehydration 4 (44.4%) 6 (85.7%) 6 (66.7%) 3 (60.0%) 5 (100%) 16 (66.7%) 6 (66.7%) 5 (62.5%) 6 (85.7%) 16 (51.6%) 
 
Zinc 4 (44.4%) 3 (42.9%) 4 (44.4%) 3 (60.0%) 1 (20.0%) 11 (45.8%) 4 (44.4%) 6 (75.0%) 2 (28.6%) 12 (38.7%) 
 
Probiotics 8 (88.9%) 7 (100%) 8 (88.9%) 3 (60.0%) 5 (100%) 23 (95.8%) 9 (100%) 8 (100%) 6 (85.7%) 27 (87.1%) 
Haematology 
          
 
WBC x10
9
/L 10.7 (8-13) 13.6 (10-16) 12.9 (10-16) 10.2 (10-15) 7.2 (7-7) 10.2 (8-12) 11.6 (9-16) 16.3 (11-21) 12.3 (12-16) 9.7 (8-12) 
 
Neutrophils (%) 28.9 (22-40) 54.9 (39-72) 51.5 (41-55) 60.9 (55-63) 22.4 (19-26) 41.1 (32-59) 49.6 (39-64) 53.5 (43-59) 59.6 (56-62) 45 (32-52) 
 
Lymphocytes (%) 52.4 (43-60) 33.7 (18-50) 35.4 (30-38) 32.4 (26-33) 64.9 (63-67) 40 (29-49) 36.4 (21-44) 38 (37-42) 28.5 (27-31) 40.9 (33-51) 
 
Haematocrit (%) 39.3 (36-42) 35.7 (34-38) 32.9 (31-38) 37.3 (35-38) 35.3 (35-36) 36.6 (33-38) 34.7 (31-42) 36.3 (34-39) 35.4 (34-39) 35.5 (34-37) 
WBC: white blood cell count
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Table 5: Univariate logistic regression evaluating any diarrhoeal episode positive by Luminex against the remainder of the cohort (both Luminex-negative 
and diarrhoea-negative).  
Characteristic 
C. difficile Campylobacter Salmonella Shigella Adenovirus Norovirus Rotavirus 
OR 
p 
OR 
p 
OR 
p 
OR 
p 
OR 
p 
OR 
p 
OR 
p 
95%CI 95%CI 95%CI 95%CI 95%CI 95%CI 95%CI 
Age (month) 
0.87 
<0.001 
1.02 
0.546 
0.94 
0.006 
1.02 
0.569 
0.99 
0.784 
0.95 
0.006 
0.97 
0.205 
0.81-0.93 0.96-1.07 0.90-0.98 0.94-1.11 0.95-1.04 0.92-0.99 0.92-1.02 
Male sex 
2.76 
0.010 
1.24 
0.610 
1.58 
0.156 
2.77 
0.433 
1.12 
0.776 
2.33 
0.006 
2.26 
0.055 
1.28-5.94 0.54-2.83 0.84-2.97 0.44-7.13 0.50-2.51 1.28-4.24 0.98-5.20 
Growth metrics at 12m 
             
 WAZ 
1.11 
0.150 
1.10 
0.314 
1.02 
0.826 
0.62 
0.009 
1.45 
<0.001 
0.91 
0.134 
0.96 
0.655 
 
0.96-1.27 0.91-1.34 0.88-1.17 0.43-0.89 1.21-1.73 0.79-1.03 0.81-1.14 
 HAZ 
1.10 
0.131 
0.98 
0.815 
1.02 
0.715 
0.68 
0.015 
1.33 
0.001 
0.90 
0.081 
0.79 
0.003 
 
0.97-1.25 0.82-1.17 0.90-1.17 0.50-0.93 1.13-1.57 0.80-1.01 0.68-0.92 
 WHZ 
1.04 
0.574 
1.09 
0.320 
1.0 
0.995 
0.82 
0.241 
1.20 
0.03 
0.95 
0.378 
1.15 
0.064 
 
0.91-1.18 0.92-1.30 0.88-1.14 0.59-1.14 1.02-1.41 0.84-1.07 0.99-1.34 
Low maternal 
education 
0.80 
0.503 
0.63 
0.276 
0.98 
0.956 
1.12 
0.862 
0.82 
0.635 
1.55 
0.128 
1.94 
0.107 
0.41-1.55 0.28-1.44 0.53-1.81 0.30-4.22 0.37-1.83 0.88-2.71 0.87-4.35 
Rotavirus 
vaccination 
1.36 
0.503 
0.83 
0.661 
0.78 
0.448 
1.11 
0.874 
0.43 
0.074 
1.13 
0.659 
0.65 
0.292 
0.64-2.46 0.36-1.92 0.42-1.47 0.30-4.18 0.17-1.08 0.65-1.96 0.29-1.45 
Toilet^ 
              
 Chamber 
pot 
1.0 
0.996 
1.07 
0.909 
1.85 
0.274 
0.64 
0.625 
1.07 
0.909 
1.76 
0.190 
0.63 
0.393 
 
0.38-2.64 0.33-3.46 0.61-5.59 0.11-3.86 0.33-3.46 0.75-4.12 0.22-1.81 
 Floor 
1.04 
0.964 
1.58 
0.606 
4.18 
0.038 
3.19 
0.252 
4.18 
0.038 
1.35 
0.670 
1.04 
0.964 
 
0.20-5.30 0.28-8.84 1.08-16.1 0.44-23.2 1.08-16.1 0.34-5.42 0.20-5.30 
Diaper* 
1.48 
0.291 
1.84 
0.198 
3.68 
<0.001 
1.72 
0.476 
0.87 
0.772 
2.13 
0.015 
1.27 
0.578 
0.71-3.1 0.73-4.67 1.9-7.12 0.39-2.57 0.33-2.28 1.16-3.90 0.55-2.96 
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Household 
crowding
†
 
1.02 
0.945 
1.09 
0.844 
1.42 
0.289 
9.81 
0.757 
0.59 
0.196 
0.93 
0.794 
0.74 
0.442 
0.52-2.04 0.47-2.52 0.74-2.73 0.22-3.04 0.27-1.31 0.53-1.62 0.25-1.58 
Regular 
probiotics 
0.82 
0.599 
1.14 
0.764 
1.62 
0.123 
1.52 
0.536 
1.78 
0.158 
1.46 
0.180 
2.62 
0.014 
0.40-1.70 0.49-2.64 0.88-2.99 0.40-5.70 0.80-3.96 0.84-2.53 1.22-5.62 
* controlled by age; ^Flush toilet as the reference category; † >2 people/room; OR: odds ratio; CI: confidence interval; WAZ: weight for age Z-score; HAZ: 
height for age Z-score; WHZ: weight for height Z-score
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Figure 1: Pathogen specific incidence of a selection of aetiologies detected by the Luminex 
Gastrointestinal Pathogen Panel across age groups. Top row: incidence of ten pathogens per 
100 child years of follow up in 12-23 months, 24-35 months and ≥36 months of age. Bottom row: 
proportion of diarrhoeal stools that were positive for each pathogen, 12-23 months, 24-35 months 
and ≥36 months of age. C diff: Clostridium difficile; Campy: Campylobacter spp.; O157: E. coli 
O157; ETEC: Enterotoxigenic E. coli; Salm: Salmonella spp.; Shig: Shigella spp.; Adeno: 
adenovirus; Noro: norovirus; Rota: rotavirus; Crypto: Cryptosporidium. 
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Figure 2: Coinfection matrix. Each detected pathogen is displayed in matrix format. The color 
represents the correlation of coinfection between both pathogens: the darker the red, the more 
positive the Pearson correlation coefficient and the darker the blue, the more negative the Pearson 
correlation coeffficient. C diff: Clostridium difficile; Campy: Campylobacter spp.; O157: E. coli 
O157; ETEC: Enterotoxigenic E. coli; Salm: Salmonella spp.; Shig: Shigella spp.; STEC: Shiga-
toxin producing E. coli; Adeno: adenovirus; Noro: norovirus; Rota: rotavirus; Crypto: 
Cryptosporidium; Ent Hist: Entamoeba histolytica. 
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Figure 3: Seasonality of incidence of selected pathogens. The monthly incidence per 100 child 
years of follow up of each pathogen is shown in a different panel and in a different color, with 
pathogen names at the top of each plot.  
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Abstract  
Background: Shigella sonnei is an emergent and major diarrheal pathogen for which there 
is currently no vaccine. We aimed to quantify duration of maternal antibody against S. 
sonnei and investigate transplacental IgG transfer in a birth cohort in southern Vietnam.  
 
Methods and Results: Over 500-paired maternal/infant plasma samples were evaluated for 
presence of anti-S. sonnei-O IgG and IgM. Longitudinal plasma samples allowed for the 
estimation of the median half-life of maternal anti-S. sonnei-O IgG, which was 43 days 
(95% confidence interval: 41-45 days). Additionally, half of infants lacked a detectable 
titer by 19 weeks of age. Lower cord titers were associated with greater increases in S. 
sonnei IgG over the first year of life, and the incidence of S. sonnei seroconversion was 
estimated to be 4/100 infant years. Maternal IgG titer, the ratio of antibody transfer, the 
season of birth and gestational age were significantly associated with cord titer.  
 
Conclusions: Maternal anti-S. sonnei-O IgG is efficiently transferred across the placenta 
and anti-S. sonnei-O maternal IgG declines rapidly after birth and is undetectable after 
five months in the majority of children. Preterm neonates and children born to mothers 
with low IgG titers have lower cord titers and therefore may be at greater risk of 
serconversion in infancy.  
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INTRODUCTION 
The bacterial genus Shigella is a major contributor to the global burden of diarrheal 
disease. This genus of enteric pathogens is typically associated with disease in children 
under five years of age in industrializing regions (1), and is estimated to be responsible 
for 100,000 deaths annually (2). Shigella infections are characteristically associated with 
dysentery (blood and mucus in the stool) and can be severe in young children (3, 4). Of 
the four Shigella species, S. flexneri and S. sonnei predominate worldwide (1). S. flexneri 
is traditionally associated with disease in industrializing countries, whereas S. sonnei is 
more commonly isolated in industrialized regions. However, this distribution is changing. 
S. sonnei is globally emergent and replacing S. flexneri as the most common cause of 
bacterial dysentery (5, 6). This trend may be being exacerbated by resistance to common 
antimicrobials, with several recent reports of S. sonnei exhibiting resistance against 
fluoroquinolones and 3
rd
 generation cephalosporins in the USA, Vietnam and elsewhere 
(7–9). Improved sanitation and antimicrobial treatment remain the only current tools for 
prevention and control as there are no licensed Shigella vaccines (10). 
 
Neonates and infants are typically at increased risk from infectious agents such as 
Shigella due to immaturity of the immune system (11). While neonates have some 
capacity for cell-mediated immunity (12), humoral immunity is very limited in early life 
(13). Antibody responses in neonates are shorter, delayed in onset and of lower affinity 
than those observed in healthy adults (14). The transfer of maternal IgG antibody to the 
fetus during pregnancy confers short-term passive immunity and represents a primary 
mechanism for protection against infectious diseases at birth (11). Transport of maternal 
antibody across the placenta to fetal capillaries is mediated by the neonatal Fc receptor 
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(FcRn) (15–17) and can be affected by factors such as gestational age, maternal IgG 
concentration and infection (18–21).  
 
Maternally transferred IgG against S. sonnei in infancy has not been substantially 
investigated. Work conducted in Israel in the mid-1990s found that the concentration of 
anti-S. sonnei lipopolysaccharide (LPS) IgG present in umbilical cord plasma positively 
correlated with the concentration in maternal plasma (22). IgG against LPS, specifically 
the O-antigen component, is the best described S. sonnei immune marker as it is the major 
bacterial surface antigen exposed to the immune system during infection. Although anti-
S. sonnei-O IgG is not a definitive correlate of protective immunity (23), it is an indicator 
of some degree of acquired immunity; lack of Shigella serotype specific antibody is 
associated with an increased risk of symptomatic disease (24, 25). Furthermore, titers of 
anti-S. sonnei-O IgG rise significantly after symptomatic infection (22, 26, 27), with titers 
doubling ten weeks post-infection (26, 28). Previous work from Vietnam in the late 1980s 
showed that anti-S. sonnei-LPS and anti-S. flexneri-LPS IgG rise dramatically from birth, 
peak at 3-4 years of age and then permanently plateau (29).  
 
An understanding of the nature and duration of maternal antibody protection in infancy is 
important for determination of an appropriate vaccination schedule when Shigella 
vaccines eventually become available. Additionally, although IgG titers against S. flexneri 
and S. dysenteriae type I in Vietnam were found to be high in children and adults in the 
early 1990s (27, 29), exposure to Shigella has not been measured in a contemporary 
Vietnamese population. As S. sonnei is now the predominant Shigella species in Vietnam 
(30), we hypothesized there would be substantial evidence of population exposure and S. 
sonnei maternal antibody transfer in this rapidly industrializing country. Therefore, we 
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aimed to quantify maternal anti-S. sonnei-O antibody decay using the largest sample size 
to date, with over 500 paired mother and infant plasma samples. We also investigated 
transplacental IgG transfer and determined the incidence of S. sonnei seroconversion in 
infancy in southern, urban Vietnam. 
 
METHODS 
Ethical approval 
Written informed consent was required from all enrolled families. Ethical approval was 
granted from Hung Vuong Hospital, Oxford Tropical Research Committee as well as the 
London School of Hygiene & Tropical Medicine for the main cohort study. Ethical 
approval was also granted from the Hospital for Tropical Diseases in HCMC and 
OxTREC for the studies collecting acute and convalescent plasma samples from culture-
positive Shigella and Salmonella cases for ELISA validation.  
 
Study population 
The birth cohort population and methodology has been described previously in detail 
(31). Briefly, mothers delivering at Hung Vuong obstetric hospital in Ho Chi Minh City 
(HCMC) were invited to enroll during either an antenatal visit in the final month of 
pregnancy or at the time of hospital admission for delivery. Children born between 
January and December 2013 in HCMC were included in the analysis presented here. 
Pregnant women were eligible if they lived in district 8 of HCMC (a previously identified 
endemic hotspot for Shigella (30)), were aged 16 years or older and were HIV 
seronegative at the time of birth. Mothers answered a baseline questionnaire and blood 
(umbilical cord and venous) samples were collected in EDTA tubes. After delivery, 
infants were recalled regularly for routine follow up visits. A 1ml EDTA blood sample 
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was collected at the 4, 9 and 12 month visits. All blood samples were separated into cells 
and plasma and stored at -20
o
C until required.  
 
S. sonnei anti-O antigen ELISA 
Antibody (IgG and IgM) against S. sonnei O-antigen were measured using an enzyme-
linked immunosorbent assay (ELISA) in maternal, umbilical and longitudinally collected 
infant plasma samples. Purified S. sonnei O-antigen was extracted as previously described 
(32) and provided by Sclavo Behring Vaccines Institute for Global Health (Siena, Italy). 
For the ELISA assays, 96-well microtiter plates (Maxisorb; NUNC) were coated 
overnight with 0.5mg/mL S. sonnei O-antigen in PBS pH 7.0 at 4
o
C, plates were then 
washed and blocked in PBS containing 5% skimmed milk powder for 2 hours. After 
washing, 100μl of each plasma sample (diluted at 1:200 in PBS containing 1% skimmed 
milk) were added and plates were incubated for 2 hours at room temperature. IgG and 
IgM against S. sonnei O-antigen were detected by incubation with alkaline phosphatase 
directly conjugated anti-human IgG/IgM for 1 hour. Plates were developed by p-
nitrophenyl-phosphate solution (Sigma) and were read at absorbance 405nm and 490nm 
by an ELISA platereader (Microplate reader, Biorad). Each plate contained a 2-fold 
serially diluted pool of anti- S. sonnei-O antigen human plasma (primary concentration 
1:200). A standard curve was generated from the corresponding optical density (OD) and 
ELISA units using a 4-parameter logistic regression fit. One ELISA unit (EU) was 
defined as the reciprocal dilution of the standard plasma that gave an absorbance value 
equal to 1 in this assay. The ELISAs were done in duplicate. Antibody (IgG and IgM) 
units in the cohort members’ plasma were calculated relative to this standard each time 
the assay was performed. Acute and convalescent plasma samples for the ELISA 
validation were derived from pediatric culture-positive S. sonnei and Salmonella 
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dysentery cases presenting to either the Hospital for Tropical Disease in HCMC as part of 
another ongoing study.   
 
Statistical analyses 
Geometric mean titers (GMT) were calculated to summarize anti-S. sonnei-O IgG in 
maternal and cord plasma. Paired t-tests were used to compare log10 titers between paired 
maternal/cord samples. Analysis of variance (ANOVA) with Bonferroni correction for 
multiple comparisons was used to compare maternal and cord log-transformed antibody 
titers within categorical groups. The ratio of maternal transfer was compared across 
groups using the Kruskal-Wallis (KW) test with Dunn’s test for multiple comparisons 
(33). Linear mixed effects modeling was used to assess the trajectory of infant log10 titers 
from birth to 20 weeks to account for within-participant association over time. The half-
life of IgG titer was calculated as the time at which the predicted IgG titer would decrease 
by 50% from the cord blood titer. The population half-life was derived using the formula: 
− log10(2)
𝑏1
 
 with 𝑏1 equal to the slope of the fixed effect. The 95% confidence interval (CI) for the 
population level half-life was derived from the CI of the slope of the fixed effect. 
Children with a 4-fold rise between serial titers or those who were aged <6 months 
without a decrease in IgG titer were censored after the time point prior to the increase or 
no decrease, respectively (34). 
 
A Kaplan Meier survival curve was generated to investigate the time taken for titers to 
fall below a detectable threshold of 10.3EU. This threshold value was determined by 
calculating the mean titer value of the observation preceding a 4-fold rise in titer in 
infants that had a 4-fold rise with a gap between pre and post-seroconversion samples no 
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greater than 24 weeks (n=15). None of the cord plasma titers and less than 1% (2/502) of 
the maternal plasma samples had titers that fell below 10.3EU. For the Kaplan Meier 
estimation, infants were censored either when they (1) dropped below 10.3EU (2) had any 
rise in IgG titer or (3) were lost to follow up. Finally, linear regression was used to 
evaluate the effect of covariates on anti-S. sonnei-O IgG cord titer as well as the 
relationship between log10 cord titer and log10 increase in titer between serial follow up 
visits. All analyses were performed in STATA v13 (TX, USA) with the exception of the 
mixed effects modeling which was performed in R (version 3.0.2) using the lme4 package 
(35). Plots were made in R using the ggplot package v1.0.1 (36). 
 
RESULTS 
ELISA validation 
We firstly validated the anti-S. sonnei-O ELISA in a population of Vietnamese children 
hospitalized with dysentery with acute and convalescent plasma samples. All tested (7/7; 
100%) stool culture-positive S. sonnei cases presenting to hospital had >4 fold rise 
(median: 104-fold; range: 22-410) in IgG titer regardless of the number of days between 
the acute and convalescent samples (median: 116 days; range: 13-202). The IgM titers 
against S. sonnei O-antigen of the seven responding children also increased dramatically  
(median: 9-fold, range:3-64). Twenty culture positive Salmonella cases from the same 
study did not generate an S. sonnei O-antigen IgG response (median fold titer increase: 
1.1, range: 0-2.0), with limited IgM response as well (median: 1.4-fold, range: 0-58) (data 
not shown). 
 
Cohort baseline characteristics 
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Of the 503 infants enrolled into the birth cohort in 2013, 52% (260/503) were male, 4% 
(21/503) were born preterm (<37 weeks of gestation) and 5% (23/503) were of low birth 
weight (<2.5kg) as shown in Table 1. The median maternal age was 28 years 
(interquartile range (IQR): 25-31), with just under half of all mothers (244/503; 49%) 
reporting at least a higher secondary education. The median maternal gravidity was 2 
(IQR: 1-3) and the mean duration of infant follow up was 337 days (range: 1-399 days). 
A total of 58% (292/503) infants enrolled returned for all three follow up appointments 
where a blood sample was collected (Figure 1A). A further 78% (393/503) returned for at 
least two blood-draw appointments, and 86% (432/503) for at least one follow up blood-
draw appointment. There were no major demographic or socioeconomic differences 
between the families of infants who did not return for all four follow up visits (211/503; 
42%) and those that did return for all four visits (292/503; 58%) (Table 2). 
 
The decay of maternal anti-S. sonnei-O IgG and incidence of seroconversion 
The anti-S. sonnei-O IgG and IgM titers in infants over the first 12 months of life are 
shown in Figures 1B and 1C, respectively. Using samples collected within 20 weeks of 
birth, we estimated the median half-life of anti-S. sonnei-O IgG to be 43.2 days (95%CI: 
41.9 – 44.5 days). As shown in Figure 2, by 18.7 weeks (95%CI: 18.1-20.1 weeks) 50% 
of infants had undetectable levels of anti-S. sonnei-O IgG. A total of 16 children had a 
>4-fold rise in anti-S. sonnei-O IgG titer in the first year after birth (3.2%), the majority 
of which occurred between 4-9 months (8/16, 50%), or 9-12 months (6/16, 38%) after 
birth (Figure 2). Critically, a higher fold-rise in anti-S. sonnei-O IgG over the first 12 
months of life was associated with a lower cord titer (p<0.001; linear regression). There 
were 463.5 infant years of follow up in this cohort, leading to a seroconversion rate 
(defined by >4-fold rise in titer) of 3.5/100 years of follow up in the first 12 months of 
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life. Two children did not have a detectable decrease in IgG titer between birth and 20 
weeks of life (0.4%). Furthermore, 49/503 infants (10%) had a 2-fold rise in anti-S. 
sonnei-O IgG over the course of the first 12 months of life, the majority of which (25/49, 
51%) occurred between 9-12 months of age. Out of the 503 infants enrolled in the cohort, 
162 (32%) had a rise (any) in titer over the first year of life, which were more commonly 
detected between 9-12 months of age (84/162; 52%).  
 
Maternal antibody transfer  
The geometric mean titers of anti-S. sonnei-O IgG in cord plasma and maternal plasma 
were 234.1EU (range: 21.6-3,687.6EU) and 167.4EU (range: 3.75-2,553EU), respectively 
(Table 2). The median ratio of cord:maternal plasma anti-S. sonnei-O IgG was 1.32 
(range: 0.3-12.4) (Table 2). Anti-S. sonnei-O IgG titers in cord plasma were consistently 
and significantly higher than those in maternal plasma (Table 2), with the exception of 
babies born preterm (p=0.71, paired t-test of log10 titers). The ratio of maternal transfer in 
preterm babies (median: 1.13) was significantly lower than in babies born 37-40 weeks 
(median: 1.35) (p=0.02; KW). Furthermore, the transplacental transfer ratio in first-
pregnancy mothers (median: 1.38) was moderately higher than in mothers that had had 
previous pregnancies (median: 1.30, p=0.066; KW). The maternal transfer ratio was also 
slightly greater in younger mothers (<28 years) than in mothers ≥28 years of age (median: 
1.36 versus 1.29, respectively; p=0.065; KW). Finally, the transplacental transfer ratio 
was significantly higher in infants born in January – March (median: 1.70) and in April – 
June (median: 1.90) compared to those born in July – September (median: 1.14) and 
October – December (median: 1.12) (Table 3).   
 
Factors influencing anti-S. sonnei-O cord blood antibody titers 
176 
 
Anti-S. sonnei-O cord IgG titer was associated with several covariates in a univariate 
analysis (Table 3). However, after controlling for the effects of confounding in an 
adjusted analysis the only covariates that remained significantly associated with anti-S. 
sonnei-O cord IgG titer were ratio of transplacental IgG transer, maternal IgG titer and 
the season of birth. As shown in Figure 3A, anti-S. sonnei-O cord IgG titers in babies 
born in the first half of the year were higher than those born in the second half of the year. 
The ratio of anti-S. sonnei-O IgG maternal transfer was also elevated in the first half of 
the year compared to the later months (Figure 3B). Significantly, the ratio of 
transplacental transfer was higher in mothers with low IgG at the time of birth (Figure 
3C) (p<0.001; linear regression of log10 maternal titers).  
 
On additional analysis we found that maternal IgM increased (Figure 3D) from May to 
July, plateauing in the latter months of the year, suggesting that some mothers were likely 
exposed to S. sonnei at the time of birth during April-June. Maternal IgG levels did not 
significantly change throughout the year, although the titers were generally high, 
suggesting previous and potentially sustained exposure. The combination of low existing 
maternal IgG in some mothers during April – June and the increased the ratio of 
transplacental transfer during this period lead to an overall elevated anti-S. sonnei-O IgG 
in babies born during this period, which may be during a period of increased seasonal S. 
sonnei transmission in HCMC.  
 
DISCUSSION 
S. sonnei is an emergent and increasingly antimicrobial resistant diarrheal pathogen. As 
such S. sonnei is a growing challenge in Vietnam and other similarly industrializing 
countries (5, 6, 37–42). The aims of this study were: 1) to quantify the duration of 
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maternal IgG in infants, 2) to measure incidence of S. sonnei seroconversion in the first 
year of life and 3) to examine transplacental IgG transfer during pregnancy. As S. sonnei 
vaccines are in development (23), understanding the potential of maternal immunity in 
infants will be critical for evaluating future vaccine efficacy and identifying the infant 
groups that are most at risk of S. sonnei seroconversion (4). 
 
The estimated half-life of maternal anti-S. sonnei-O IgG (43 days, 95%CI: 42-45 days) is 
similar to that of Haemophilus influenzae (33 days), pertussis (36-40 days) and S. 
pneuomoniae (35 days)  (43–45). However, as the sampling was infrequent in the early 
weeks after birth these data should be interpreted with caution. Nevertheless, it is 
apparent that maternal antibody wanes rapidly and by five months of age the majority of 
infants had no circulating maternal antibody and are likely at increased risk of infection. 
Correspondingly, evidence of S. sonnei exposure in infants in our cohort suggests an 
incidence of seroconversion of approximately 4/100 infant years of follow up in HCMC. 
Yet given the known lack of general humoral immune responses against polysaccharides 
during infancy (13), in addition to loss to follow up, this seroconversion incidence is 
likely an underestimate.   
 
We found that lower cord titers were associated with higher fold-increases in anti-S. 
sonnei-O IgG titer in the first year of life in our cohort, suggesting that neonates born 
with lower cord titers are at increased risk of seroconversion during infancy. The most 
important influences on anti-S. sonnei-O cord titer were maternal IgG titer and the ratio of 
transplacental transfer, which were inversely correlated. Such a relationship is due in part 
to saturation of the Fc receptor, as IgG that is not bound is digested by lysosomal 
enzymes inside the syncytiotrophoblast (11, 46). The negative relationship between 
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maternal IgG concentration and transplacental transfer ratio has been suggested to 
demonstrate the existence of a mechanism to protect the newborn through strengthening 
the transfer of antibody when maternal levels are not optimally protective (47, 48). 
Furthermore, it has been found that a higher total maternal IgG concentration may lead to 
reduced transfer efficiency of both total and specific IgG (21), with some suggestion of 
receptor competition among antigen-specific IgG for the limited number of placental Fc 
receptors available (20).  
 
Neonates tended to have elevated anti-S. sonnei-O IgG titers compared to mothers in our 
cohort. Such a phenomenon has been reported for a variety of pathogens including 
Klebsiella pneumoniae, Escherichia coli and Pseudomonas aeruginosa (18, 47, 49). 
However, neonates born preterm in this cohort did not have an increased anti-S. sonnei-O 
titer relative to their mothers. As the majority of IgG is acquired by the fetus during the 
last four weeks of pregnancy (50), it follows that preterm neonates would lack maternal 
immunity and are potentially at increased risk for infections in the first few months of 
life. Furthermore, we found that children born to mothers with lower IgG titers had lower 
cord titers themselves and are at increased risk of exposure.  
 
Interestingly, we noted a seasonal pattern to both cord plasma titers as well as the ratio of 
transplacental transfer in our cohort. Cord titers and the transplacental transfer ratio were 
higher in the second quarter of the year. Given the inverse relationship between maternal 
IgG titer and transfer ratio, we propose that this period may represent a time of increased 
transmission and, therefore, exposure to S. sonnei in HCMC. This hypothesis was 
supported by the observed increase in maternal IgM titer between May and July 
(representing acute infection), suggesting that mothers’ existing immune response may be 
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naturally boosted during this time. If S. sonnei transmission in HCMC is more common 
between April and June then infants born in during this time are likely better equipped 
against S. sonnei exposure at birth as the cord titers are highest during this season. 
However, annual trends are difficult to evaluate from our yearlong dataset.  
 
There were several limitations with this study. Firstly, the infrequent early blood samples 
from infants prevented high-resolution temporal analyses regarding maternal half-life 
duration and survival analysis of the waning of maternal IgG. Next, the lack of a similar 
cohort from a non-endemic area limits our ability to fully interpret the serology data in an 
epidemiological context. Furthermore, a lack of disease data prohibits an analysis of the 
protective effect of presence of antibody as well as a more detailed analysis of anti-S. 
sonnei-O IgG and IgM response in infants after infection. However, the major strength of 
this study is the cohort design and relatively limited loss to follow up which enables us to 
generalize our conclusions to Vietnamese infants in urban HCMC. In the future, 
investigations into additional protective factors against Shigella, such as breastfeeding, 
may be warranted (51).  
 
In summary, S. sonnei exposure is common in HCMC and maternal IgG is readily 
transferred across the placenta, waning by 5 months of age in the majority of infants. In 
the event of licensure of a sufficiently safe and immunogenic S. sonnei vaccine, it would 
be prudent to vaccinate after the waning of maternal IgG in settings such as HCMC. 
Furthermore, we found that neonates have a higher concentration of IgG compared to 
mothers in most cases, and the ratio of transplacental transfer is inversely related to the 
maternal anti-S. sonnei-O IgG titer. Finally, we identified those likely to be more at risk 
of S. sonnei exposure in infancy to include preterm neonates and those born to mothers 
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with lower IgG titers. Therefore, appropriate monitoring and prevention strategies can be 
targeted to such groups. 
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Table 1: Baseline characteristics of 503 Vietnamese infants enrolled in the birth cohort in 
2013 
Characteristic 
n (%),  
median (IQR) 
Male sex 260 (51.7) 
Gestational age (wks) 39 (38-40) 
 
Preterm (<37 wks) 21 (4.2) 
Birth weight (kg) 3.15 (2.9-3.4) 
 
Low birth weight (<2.5kg) 23 (4.6) 
Vaginal delivery 288 (57.3) 
Breastfed during month 1 
 
 
Exclusively 215 (43.0) 
 
Plus formula 243 (48.6) 
 
No, only formula 42 (8.4) 
Gravidity 2 (1-3) 
Maternal education 
 
 
Lower secondary or below 255 (50.7) 
 
Higher secondary or above 248 (49.3) 
Maternal age (years) 28 (25-31) 
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Table 2: Demographic and socioeconomic characteristics of infants with plasma samples 
available from four follow up visits (0, 4, 9 and 12 months of age) and those who 
attended less than four visits, n(%) 
Characteristic 
<4 visits 4 visits 
p
a
 
n=211 n=292 
Vaginal birth 111 (52.6) 177 (60.6) 0.073 
Male infant 113 (53.6) 147 (50.3) 0.477 
Infant low birthweight 9 (4.3) 14 (4.8) 0.779 
Any previous children 128 (60.7) 185 (63.4) 0.539 
Maternal age ≥28 years 109 (51.7) 150 (51.4) 0.949 
Low maternal education 106 (50.2) 142 (48.6) 0.722 
Household crowding 116 (55) 185 (63.4) 0.059 
Infant cord log10 titer > 2.3^ 122 (57.8) 151 (51.7) 0.175 
Preterm (<37 wks) 9 (4.3) 12 (4.1) 1.00 
Breastfed during month 1 
   
 
Exclusively 89 (42.6) 126 (43.3) 0.726 
 
Plus formula 100 (47.8) 143 (49.1) 
 
 
Formula + food 20 (9.6) 22 (7.6) 
 
Mother ethnic minority 21 (10) 21 (7.2) 0.269 
Father ethnic minority 26 (12.3) 24 (8.2) 0.129 
Watersource 
   
 
Piped home 144 (68.2) 208 (71.2) 0.73 
 
Bottled 63 (29.9) 80 (27.4) 
 
  Other 4 (1.9) 4 (1.4)   
a
p-value derived from chi-square or Fisher’s exact test, ^median  
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Table 3: Geometric mean titers (GMT) of anti-S. sonnei-O IgG in maternal and cord plasma and the ratio of cord:maternal IgG titer  
Category n pairs 
Maternal IgG Cord IgG Median ratio Comparison 
a
 
GMT (range) GMT (range) (range) p value group 
Total 503 167.4 (3.75-2553.7) 230.8 (0.22-3687.6) 1.33 (0-12.4) 
  
Gestational age 
      
 
<37 weeks (1) 21 190.8 (48.5-545.8) 197.4 (49.5-546.8) 1.13 (0.4-2.6) 0.019 1:2 
 
37-40 weeks (2) 549 166.5 (3.7-2553.7) 232.1 (0.22-3687.6) 1.35 (0-12.4) 0.130 1:3 
 
>40 weeks (3) 23 165.7 (22.3-1175.0) 237.7 (68.8-1163.3) 1.33 (0.6-6.2) 1.000 2:3 
Sex
b
 
      
 
Female 243 149.2 (8.2-2553.7) 209.9 (0.22-2140.9) 1.37 (0-12.4) 0.177 
 
 
Male 260 186.4 (3.7-2524.2) 252.1 (23.1-3687.6) 1.28 (0.3-11.2) 
  
Birthweight 
      
 
<2500g 23 150.8 (26.1-1280.1) 195.9 (42.4-2140.9) 1.25 (0.5-3.8) 0.515 
 
 
≥2500g 480 168.3 (3.7-2553.7) 232.6 (0.22-3687.8) 1.33 (0-12.4) 
  
Gravidity 
      
 
1 190 150.5 (3.7-2553.7) 216.7 (0.2-2824.8) 1.39 (0-12.4) 0.066 
 
 
>1  313 178.6 (15.7-2524.2) 239.7 (23.1-3687.6) 1.3 (0.3-11.2) 
  
Maternal age 
b,c
 
      
 
<28 years 244 138.7 (3.7-1530.9) 204.5 (1.1-2824.8) 1.36 (0.3-12.4) 0.065 
 
 
≥28 years 259 199.9 (20.6-2553.7) 258.6 (0.22-3687.6) 1.29 (0-8.3) 
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Maternal education 
     
 
Lower secondary or below 255 179.9 (3.7-2553.7) 250 (26.7-3687.6) 1.29 (0.3-12.4) 0.449 
 
 
Higher secondary or above 248 155.5 (15.7-2524.2) 212.5 (0.22-3206.5) 1.35 (0-11.2) 
  
Maternal IgM 
c
 
      
 
≤1.37 253 158 (3.7-2553.7) 268.4 (22.1-2824.8) 1.66 (0.37-12.4) <0.001 
 
 
>1.37 250 177.5 (15.7-2524.2) 203.8 (21.6-3687.6) 1.16 (0.3-11.2) 
  
Season 
c
 
      
 
Jan-Mar (1) 89 148.2 (3.7-2553.7) 244.4 (34.1-2824.8) 1.7 (0.6-11.8) 0.024 1:2 
 
Apr-Jun (2) 133 174.3 (8.2-1596.0) 358.3 (65.3-3687.6) 1.9 (0.4-12.4) <0.001 1:3 
 
Jul-Sep (3) 161 162.6 (15.7-2524.2) 181.8 (22.1-3206.5) 1.14 (0.3-11.2) <0.001 1:4 
 
Oct-Dec (4) 120 182.3 (33.5-1969.7) 187 (0.22-2123.2) 1.12 (0-5.8) <0.001 2:3 
      
<0.001 2:4 
            1.000 3:4 
a 
p-values comparing ratio of transfer between categories of each characteristic, p-values corrected for multiple comparisons are shown with 
groups indicated in parentheses next to the group name ; 
b
 significant difference in log10 titers of maternal plasma per category; 
c
 significant 
difference between log10 titers of cord samples per category ; titers are shown in ELISA Units (EU) 
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Table 4: Univariate and multiple linear regression measuring the effect of different 
covariates on the outcome of log10 cord anti-S. sonnei-O IgG titer  
Characteristic 
Cord blood IgG titer 
univariate adjusted 
beta p beta p 
Cord:maternal IgG ratio 0.06 0.595 1.36 <0.001 
Infant 
    
 
Male sex 0.07 0.067 0.00 0.850 
 
Gestational age 0.04 0.006 0.01 0.549 
 
Birthweight 0.08 0.102 -0.01 0.504 
Maternal 
    
 
Age 0.01 0.001 0.00 0.246 
 
Low education -0.06 0.123 0.01 0.410 
 
Gravidity 0.03 0.088 0.00 0.921 
 
Log10 IgM -0.14 0.006 -0.01 0.798 
 
Log10 IgG 0.76 <0.001 1.01 <0.001 
Season 
    
 
Jan-Mar 0.13 0.013 0.02 0.170 
 
Apr-Jun 0.29 <0.001 0.08 <0.001 
 
Jul-Sep 1.00 - 1.00 - 
 
Oct-Dec 0.04 0.417 0.01 0.637 
Beta values represent the slope of the linear association and p-values demonstrate whether 
the slope is significantly different from the null hypothesis of 0.   
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Figure 1: Anti-S. sonnei-O antibody levels in the first year of life in a cohort of 503 
Vietnamese children 
(A) Count of the number of assayed infant plasma samples at different ages in the first 
year after birth. Anti-S. sonnei-O IgG (B) and IgM (C) titers shown over time for each 
individual in the cohort on a log10 scale. 
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Figure 2: Kaplan Meier curve showing the proportion of infants with detectable 
anti-S. sonnei-O IgG in the first year after birth 
The proportion of infants with detectable anti-S. sonnei-O IgG censored by (1) when their 
titer dropped below 10.3EU (see methods), (2) had any detectable increase in IgG titer or, 
(3) lost to follow up. The number of infants with detectable antibody at each time point 
are shown below the x-axis.  
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Figure 3: Temporal anti-S. sonnei-O antibody cord titers and transplacental 
transfer dynamics (A) Anti-S. sonnei-O IgG cord plasma titers shown by month of birth 
on a log10 scale. (B) The ratio of cord:matneral anti-S. sonnei-O IgG titer by month of 
birth. (C) Scatterplot showing the relationship between maternal anti-S. sonnei-O IgG 
titers and the ratio of cord:maternal plasma transfer. (D) Maternal anti-S. sonnei-O IgM 
titers shown by month of birth on a log10 scale. 
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10 RESEARCH PAPER 8:  The clinical implications of reduced 
susceptibility to fluoroquinolones in paediatric Shigella sonnei and 
Shigella flexneri infections 
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10.1 Supplementary figures 
 
Figure S1: The proportions of S. flexneri and S. sonnei isolates exhibiting 
antimicrobial resistance 
A bar chart showing the proportion of isolates fully resistant to each antimicrobial 
according to 2014 CLSI guidelines.5 S. sonnei are shown in dark grey and S. flexneri in 
light grey. AMP: ampicillin; CHL: chloramphenicol; CIP: ciprofloxacin; CRO: ceftriaxone; 
GAT: gatifloxacin; GEN: gentamycin; NAL: nalidixic acid; OFX: ofloxacin; SXT: 
cotrimoxazole; TET: tetracycline; MDR: multidrug resistant (defined as resistance to 
ampicillin, chloramphenicol and cotrimoxazole); ESBL: extended-spectrum beta 
lactamase phenotype.  
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Figure S2: Distribution of minimum inhibitory concentrations of S. sonnei and S. 
flexneri against ciprofloxacin and gatifloxacin relative to the CLSI resistance 
breakpoint Density plots showing the Z-scores of log2MICs (mg/L) with the mean 
cantered on the CLSI breakpoint (ciprofloxacin: 1mg/L, gatifloxacin: 8mg/L). Gatifloxacin 
MICs are shown in the dashed line and ciprofloxacin MICs are shown in the solid line. 
Plots are separated by species: (A) S. flexneri and (B) S. sonnei. CIP: ciprofloxacin; 
GAT: gatifloxacin.  
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Figure S3: The distribution of minimum inhibitory concentrations of gyrA 
mutations against four fluoroquinolones 
Density plots showing MICs (mg/L) to the (fluoro)quinolones for each gyrA mutation. 
Isolates without a gyrA mutation are shown in light grey, isolates with the A87T mutation 
are shown in dark grey and isolates with the S83L mutation are shown in black. The 
MICs of (A) nalidixic acid (B) gatifloxacin (C) ciprofloxacin and (D) ofloxacin are shown 
on a log2 scale.   
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11 DISCUSSION 
 
Diarrhoeal disease continues to plague children living in disadvantaged societies. 
Diarrhoea (at least three loose or watery stools in a 24 hour period [1]) not only presents 
an often significant mortality risk in early life, but repeat infections during childhood lead 
to reduced physical and cognitive development [2–6]. The MDGs have witnessed a huge 
drop in childhood mortality globally since 1990 [7], but children in poor regions are 
disproportionately more likely to die or suffer from morbidity due to diarrhoea [8]. 
Diarrhoeal infections due to the Gram-negative bacteria Shigella are of particular 
concern due to the clinical severity, ease of spread and alarming levels of AMR [9–11]. 
Promising Shigella vaccine candidates are under development [12]. Vietnam, though 
progressing economically [13], still faces a considerable burden of childhood morbidity 
due to diarrhoeal disease [14]. In order for an effective Shigella vaccine to be potentially 
be introduced as a public health tool in this setting, more information regarding the 
epidemiology of the pathogen is required. Therefore, the principal aim of this thesis was 
to quantify the burden of diarrhoeal disease in HCMC, with a specific focus on Shigella 
infections, to determine whether a Shigella vaccine is necessary in this setting.  
11.1 Summary of key findings 
Work from this thesis has confirmed that diarrhoeal disease remains a significant cause 
of childhood morbidity in HCMC, with a community-based incidence of 70 episodes/100 
child years of observation (CYO). Furthermore, Shigella incidence was found to be 
1.5/100 CYO in children aged 2-5 years in the community which is substantial, but not as 
high as rotavirus (4.8/100 CYO) or norovirus (12.5/100 CYO). Children living at low 
elevation in the centre of the city were found to be at increased risk of hospitalised 
diarrhoeal disease, particularly during periods of elevated temperature of river levels. 
Additionally, AMR was identified against a variety of antimicrobials in Shigella, and 
organisms harbouring mutations against fluoroquinolone activity were shown to survive 
for a longer duration in the presence of ciprofloxacin in vitro, suggesting an 
epidemiological advantage of these strains in the face of growing fluoroquinolone 
resistance. Finally, maternal antibodies against S. sonnei are efficiently transferred 
across the placenta during pregnancy and circulate in the infant for 43 days in HCMC, 
which should aid in determination of an eventual vaccination schedule in locations where 
it is necessary. 
In conclusion, data presented in this thesis do not warrant a Shigella vaccine presently in 
HCMC as the burden is not large relative to viral infections such as rotavirus and 
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norovirus. However, given the relentless growth of AMR in Shigella in addition to recent 
reports of Stx-producing S. flexneri and S. sonnei [15,16], vigilant epidemiological and 
molecular surveillance is required. Should either fully resistant (to first and second line 
therapies) or Stx-producing Shigella come to predominate in HCMC in the future, a 
vaccine may well prove necessary and economically feasible to avert a likely increase in 
morbidity and mortality. In the meantime, promotion of an integrated set of preventive 
interventions such as breastfeeding and water, sanitation and hygiene (WASH) 
measures is warranted.  
11.2 Aetiology and burden of hospitalised diarrhoea 
Results from the hospital-based aetiology study in Chapter Three suggest that 
hospitalised diarrhoea is most common in young children (8-20 months) in HCMC and is 
most often due to rotavirus infection (42%, 590/1,419 cases). Norovirus (17%, 241/1,419 
cases) was also quite common. Shigella infections presenting to hospital were rare (3%, 
48/1,419) though they were found in older children (median 31 months) and were often 
clinically severe. The isolated Shigella organisms showed dramatic AMR against several 
antimicrobials, including ampicillin and nalidixic acid; three-quarters of the Shigella 
isolates were also ESBL-producing. Though the hospital burden of Shigella infections 
may not be large in comparison to viral aetiologies, treating it appropriately in this setting 
may be challenging, especially considering the delay in antimicrobial susceptibility profile 
results (~5 days post admission) in clinical settings. 
Previous estimates of Shigella burden from passive surveillance in hospitals in Vietnam 
are scarce [17], with no recent reports from HCMC. However, two hospital-based studies 
from the early 2000s from hospitals in Hanoi isolated Shigella by microbiological culture 
in 2.7% (48/587) and 22% (21/249) of samples from children with diarrhoea [18,19], 
reflecting substantial variability in prevalence. In a similar study in Cambodia, the rate of 
Shigella isolation in paediatric diarrhoeal cases presenting to hospital was 5.2% (31/600) 
[20]. However, hospital-seeking behaviour biases and limitations in diagnostic capacity 
warrant caution in interpreting these data. As in Chapter Three, molecular diagnostics 
were only used for viral pathogens in the referenced studies, and therefore bacterial 
aetiologies are likely under-reported. Given the rampant use of antimicrobials in the 
community in Vietnam [21], it is likely that Shigella organisms would be difficult to culture 
at hospital presentation as patients would have sought pre-treatment at a local 
pharmacy. Molecular diagnostics, such as the Luminex platform, may aid in generating a 
more accurate estimate of Shigella prevalence in hospitalised diarrhoeal disease in this 
setting.  
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11.3 Spatiotemporal trends of hospitalised diarrhoeal disease in HCMC 
In HCMC, inner-city conditions with poor water and sanitation infrastructure are often 
home to the urban poor, particularly migrants lacking property rights [22–25]. Adding to 
this disadvantage, work from Chapter Four of this thesis demonstrates that child health 
in these impoverished areas of HCMC is vulnerable to the effects of climate change as 
children are more likely to be admitted with diarrhoea during periods of increased 
flooding or higher temperature. Considering the trajectory and magnitude of anticipated 
effects of climate change, it is likely these populations will bear a large proportion of the 
diarrhoeal disease burden in not only HCMC, but similar rapidly urbanising and climate-
sensitive locations such as Manila and Bangkok [26,27].  
Regardless of whether a vaccine is implemented in HCMC, targeted WASH interventions 
in regions like central HCMC would likely aid in reducing morbidity due to diarrhoeal 
disease in children. Large scale solutions such as improvement of water and sanitation 
infrastructure have been shown to be dramatically effective, yet are often impractical on 
a short-term scale in many impoverished regions and are only successful with committed 
financial government resources and political will [28–32]. Behaviour change efforts such 
as handwashing campaigns and household water treatment interventions, while effective 
in reducing diarrhoeal incidence in the short-term, also struggle to induce long lasting 
habit change and reduction in disease morbidity in endemic regions [33–37]. To 
realistically tackle WASH-challenges in a setting such as HCMC, particularly in poor 
communities where drinking water is often harvested through illegal taps and untreated 
sewage released into canals [23], sustained funding and government commitment are 
required [25].  
11.4 Age-specific burden of diarhhoea and Shigella infections in the community 
The burden of diarrhoeal disease in the community in HCMC remains unacceptably high, 
as shown through the birth cohort presented in Chapters Five and Eight. Passive 
surveillance for diarrhoeal disease in infants (<12 months of age) in Chapter Five led to 
an estimated diarrhoeal episode incidence of ~90/1000 years of follow up. However, 
active surveillance for diarrhoeal disease in older children (12-60 months of age) in 
Chapter Eight led to an estimated incidence of ~70/100 years of follow up. This order of 
magnitude difference in disease incidence illustrates the utility of active surveillance and 
suggests the incidence in infants, who were not included in the active surveillance of 
Chapter Eight, is likely to be much higher.  
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Our active surveillance incidence estimate of 70/100 CYO is substantially larger than that 
found in a large study conducted in the central Vietnamese coastal city of Nha Trang in 
the mid-2000’s (11.5/100 CYO) due likely to differing strategies used to capture 
diarrhoeal disease [14]. This large study, by von Seidlein et al., first performed education 
campaigns on diarrhoeal disease in the community to encourage health care attendance 
during a diarrhoeal episode and then relied on passive surveillance from designated 
local health clinics and hospitals to generate estimates of incidence [14]. Yet the overall 
diarrhoeal incidence estimate of Chapter Eight is lower than that of Isenbarger et al. who 
found a burden in Hanoi of 1.3 episodes/child/year in children under five years of age in 
the late 1990s [38], which likely reflects a true trend in declining morbidity due to 
diarrhoeal diseases in Vietnam over time as the country industrialises.  
Data from Chapters Three and Eight show Shigella is a common cause of both watery 
diarrhoea and dysentery in hospitalised and community-based diarrhoeal in young 
children in HCMC. Data from the first year of the cohort study allowed for a preliminary 
incidence estimate of Shigella diarrhoeal disease of 1.5/100 CYO, which is expected to 
grow as the cohort matures. Our Shigella incidence is three times that of a large study 
conducted a decade ago in central Vietnam and is in fact most similar to that of 
Indonesia (1.9/100/year), Pakistan (1.7/100/year) and China (1.9/100/year) from the 
same study [14]. Interestingly, even with our relatively limited number of episodes of 
Shigella within the first year, malnourished and stunted children were still significantly 
more likely to report diarrhoeal disease due to Shigella in a nested case control study, 
highlighting the population most at-risk and in need of prevention and control measures 
in this setting. When speciation was performed in the hospital-based study in Chapter 
Three, S. sonnei was isolated in the vast majority of cases (92%), suggesting that this 
species continues to dominate locally.  
Results from passive surveillance of diarrhoeal disease in Chapter Five highlight the 
burden of rotavirus in infancy, with 53% of all diagnosed samples positive for the virus. 
The active surveillance conducted in Chapter Eight confirms the importance of rotavirus, 
particularly in 12-23 month olds (7.8/100 CYO) while also highlighting the burdens of 
norovirus (17/100 CYO), Salmonella (13/100 CYO) and C. difficile (12.0/100 CYO) in 12-
23 month olds. In older children, Salmonella predominated (18/100 CYO in 24-35 month 
olds) as well as Campylobacter (14/100 CYO) and norovirus (9.0/100 CYO) infections. 
The relative lack of Cryptosporidium (1.7/100 CYO) is inconsistent with the GEMS and 
MAL-ED studies in which it was a leading aetiology in diarrhoeal disease of young 
children in impoverished regions [39,40]. This difference may be due to differing ecology 
and risk factors of diarrhoeal disease in HCMC [41].  
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11.4.1 Use of molecular diagnostics 
The Luminex platform has very high sensitivity and specificity for a wide range of 
pathogens [42–44] which allows for identification of a number of important aetiologies 
including ETEC and Cryptosporidium that are not detected through routine procedures in 
hospitals in Vietnam, or across other parts of Southeast Asia. If used routinely, the 
detection of such important pathogens may aid in not only treatment decisions but also in 
generation of hypotheses for further epidemiological and aetiological studies. 
The use of molecular diagnostics in the active surveillance cohort must be discussed 
with an element of caution, however. An obvious issue raised by the high rate of 
coinfection in Chapter Eight and the use of the Luminex in general is pathogenicity. 
Platts-Mills and colleagues recently found that Cryptosporidium, STEC and Shigella were 
more commonly associated with severe diarrhoea than other pathogens through a birth 
cohort that sampled healthy stools as well as diarrheal stools [40]. However, these 
authors also found Giardia, enteroaggregative E. coli (EAEC), atypical enteropathogenic 
E. coli (EPEC) and norovirus G1 frequently in both diarrhoeal and healthy stool samples 
[40], raising the question: if a pathogen is identified in a stool sample, is it actually 
responsible for causing disease? If a molecular diagnostic identifies an organism in a 
sample, should a clinician prescribe therapy? In order to investigate relative 
pathogenicity in the future, use of the Luminex in combination with a quantitative 
technique [45], may provide more insight into the relationship between presence of a 
pathogen and clinical disease.  
 
For example, C. difficile was identified in 15% (37/248) of stool samples from children 
12-23 months of age in Chapter Eight. C. difficile is a significant cause of severe disease 
and death globally, derived often from nosocomial infection [46,47]. Yet, C. difficile is 
known to be much less common in children than adults, and asymptomatic infection with 
toxigenic strains is common [48]. Two studies from the 1980s suggested up to 70% of 
infants can be asymptomatically colonised [49,50], though the reason for the lack of 
disease in colonised human infants is unclear [51,52]. While use of molecular 
diagnostics in settings like HCMC may provide for unprecedented diagnostic scope, 
careful clinical consideration must be given to therapeutic implications. It is 
recommended that treatment should only be considered for symptomatic C. difficile 
patients [53]. Though, it has been suggested that C. difficile circulating in children may 
represent a reservoir for infection to the wider community [54], in which case treatment 
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for an asymptomatic infection in children may represent a potential avenue for broader 
control if epidemiological data from HCMC were collected to support it. 
11.5 Maternal antibody dynamics in infancy 
If a Shigella vaccine is to be considered, an important component of vaccine rollout is the 
determination of the vaccine schedule [55]. Given too early, a vaccine may be 
neutralised by the presence of maternal antibody [56,57]. Given too late and vulnerable 
infants are put at risk unnecessarily [58]. Work from Chapter Nine of this thesis 
quantifies, for the first time, the duration of maternal IgG antibody against S. sonnei O-
antigen. The determined half-life of S. sonnei (43 days) is similar to that of other Gram-
negative bacteria (Haemophilus influenza and Bordatella) [59,60] and represents one of 
the first attempts to quantify duration of persistence of maternal IgG antibody in any 
Gram-negative enteric bacteria [61,62]. Furthermore, Chapters Three and Five 
document high rates of breastfeeding in infants in HCMC, which is known to reduce both 
duration and severity of Shigella infections in young children [63–65]. Previous work has 
shown that secretory IgA antibody directed against the Shigella LPS are present in 
breastmilk in mothers in endemic regions and can remain for >90 days [63,66,67]. 
However, as demonstrated in Appendix A of Chapter Five, over half of mothers in HCMC 
birth cohort did not exclusively breastfeed infants beyond six months of age, indicating 
children could be at risk during this time period due to both lack of remaining maternally 
transferred serum IgG and secretory IgA.   
The precise nature of the timing of a potential Shigella vaccine will depend on a number 
of factors including efficacy and safety profile in young children, route of vaccination, and 
number of required doses [12,68,69], but results from the thesis suggest that immunising 
after five months of age (and likely later) would be prudent, particularly given the disease 
burden is higher in two to three year olds. Recent commentary suggests that the 
commercial market for a Shigella vaccine would be improved if it was co-administered 
with another enteric vaccine like ETEC [12], allowing for streamlined EPI administration. 
Currently recommended rotavirus vaccine schedules call for the first dose at six weeks of 
age, coadministered with the first dose of the diphtheria/tetanus/pertussis (DTP) vaccine 
[70], which may be too early for a Shigella vaccine. The measles/mumps/rubella (MMR) 
vaccine is recommended to be given at 9-12 months of age, which, depending again on 
age-specific incidence in other areas, could be an appropriate timepoint for integration of 
a future Shigella vaccine [70]. However, it will be important to quantify the transfer and 
duration of S. flexneri serotypes as well in the event of a successful multivalent Shigella 
candidate [71]. 
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11.6 Fluoroquinolone resistance and clinical outcome of Shigella infections 
AMR in Shigella, including fluoroquinolone resistance, is an increasing problem both in 
Vietnam as well as globally [11,72–74]. In the event that a vaccine is unnecessary, 
adequate treatment will be pivotal for controlling infections and preventing onward 
transmission. Work from Chapter Ten set out to understand the impact of 
fluoroquinolone resistance on clinical outcome of shigellosis patients to better inform 
clinicians in this setting. The main conclusion was that Shigella circulating in HCMC at 
the time (mid- to late-2000s) were largely sensitive to fluoroquinolones and effectively 
treated by ciprofloxacin or gatifloxacin. The majority of isolates collected during this time 
period had only a single mutation in the gyrA gene (most commonly A87T) and had MICs 
below the current CLSI resistant breakpoint. Therefore, as long as Shigella isolates have 
an MIC below this threshold the infection can be effectively resolved with either 
ciprofloxacin or gatifloxacin. 
However, since the time the isolates evaluated in Chapter Ten were collected (2006-
2007), a substantial shift in AMR patterns has been observed. While only 2% of Shigella 
isolates collected in 2009 in Chapter Three exhibited full resistance to ciprofloxacin, rates 
have risen dramatically since. We were not able to culture all of the Shigella isolates 
collected in 2013-2014 identified by the Luminex assay in the cohort study (2/9, 22%) 
from Chapter Eight and thus have no antimicrobial susceptibility profile for these 
organisms. However, a total of 11/11 isolates collected from children in three hospitals in 
2014-2015 in HCMC from an additional ongoing study were found to be fully resistant 
(MIC > 4µg/mL) to ciprofloxacin. These isolates, along with 49 other S. sonnei organisms 
exhibiting ciprofloxacin resistance from within and outside of Asia, were sequenced and 
a clonal expansion of a triple mutant (gyrA S83L, parCS80I, gyrAD87G) was identified 
across countries including Vietnam, India, Bhutan as well as travel-associated isolates in 
Europe, America and Australia [75]. Work from Chapter Ten demonstrates that Shigella 
harbouring gyrA mutations and the qnrS gene survive significantly longer in vitro in the 
presence of high levels of fluoroquinolone, suggesting that organisms such as the triple-
mutant observed to be spreading globally may be shed into the environment for a longer 
period of time and outcompete sensitive strains in circulation. This rapid dominance of 
ciprofloxacin resistant S. sonnei has implications for not only treatment, but also the 
epidemiology of Shigella infections globally.  
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11.7 Use of a Shigella vaccine in Vietnam 
The persistence and potential growth of diarrhoeal morbidity in areas such as HCMC is 
difficult to remedy. Vaccines are without a doubt one of the most effective tools of 
modern public health and may play a major role in diarrhoeal prevention globally. Yet 
with only eight enteric vaccines licensed to date, covering only four pathogens 
(poliovirus, Salmonella Typhi, rotavirus and Vibrio cholerae) the development of future 
enteric vaccines, particularly mucosal vaccines, is a significant challenge [76–78]. It is a 
challenge worth meeting, however, given the alarming rise in AMR among bacterial 
organisms such as Shigella, which threatens to reverse progress made reducing 
diarrhoeal disease burden in recent years [79–83].  
Whether a vaccine for Shigella should be developed generally is not in doubt. The global 
morbidity and mortality of disease combined with rapidly expanding AMR warrants the 
significant time and investment required for licensure [39,40,84]. Indeed several 
promising candidates are in clinical trials currently [85,86]. However, determining 
whether a Shigella vaccine is necessary for HCMC at this time is not straightforward. 
While the documented burden in 2-5 year old children (1.5 episodes/100 CYO) is 
relatively substantial and similar to burdens in other Asian countries [14], the more 
significant burdens of other aetiologies of diarrhoeal disease identified in this thesis, 
particularly rotavirus, mandates careful consideration of available funding and political 
attention toward any future Shigella vaccine. In the context of the current healthcare 
funding situation in Vietnam, with limited financing generally and extremely strained 
resources as it stands [87,88], it is unlikely that a Shigella vaccine is worth the expense 
and effort for the limited burden of disease documented in Chapter Ten. A formal cost-
effectiveness study is warranted prior to any firm conclusions [89], but the relatively low 
morbidity documented in this thesis predicts a Shigella vaccine programme is not 
justified at this time.    
Continued surveillance, both epidemiological and molecular, are necessary however. 
While fluoroquinolones and third generation cephalosporins may currently be effective in 
the majority of patients presenting to hospital in this setting, this is not likely to remain the 
case [11]. In the event of fully AMR Shigella circulating in HCMC, vaccination may need 
to be reconsidered. Furthermore, if Stx-producing Shigella begin to circulate as has been 
observed in Haiti and the USA [15,16], the clinical severity of these infections may again 
warrant reconsideration of vaccination. Ensuring that existing surveillance systems are 
robust and timely is a worthy investment to keep abreast with this rapidly evolving 
pathogen. 
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As documented in Chapters Three, Five and Eight, a majority of the burden of 
hospitalised and community-based diarrhoea in HCMC is due to rotavirus, particularly in 
the first and second years of life. However, as shown in Chapter Eight, only 40% of 
children received at least one dose of RoV vaccine in HCMC. Instead of pursuing a 
Shigella vaccine currently, it is recommended that Vietnam use existing resources to 
continue to bolster rotavirus vaccine uptake to limit the burden of diarrhoeal disease. 
Though expensive (US$70-80), previous research has indicated that the vaccine would 
be cost-effective in Vietnam if GAVI-subsidised [90] in addition to being safe when co-
administered within the current PEI schedule [91]. Furthermore, Vietnam is working to 
develop a naturally attenuated monovalent GIP[8] vaccine candidate to produce locally in 
an effort to reduce the cost [92]. Using the current national health budget to encourage 
rotavirus vaccination would likely have a larger impact on childhood diarrhoeal morbidity 
than attempting to vaccinate against shigellosis.  
Although the advent of rotavirus vaccines will undoubtedly continue to reduce morbidity 
and mortality [93,94], prevention and control in the post-rotavirus vaccine era is not 
straightforward, as Platts-Mills and colleagues have suggested [40]. Non-vaccine based 
strategies will need to be pursued to prevent and control Shigella infections in HCMC. 
Breastfeeding is known to be protective against shigellosis, and to reduce severity and 
duration of infection in infants [64]. Yet aggressive marketing of milk formulas and 
supplements has led to a drop in prevalence and duration of breastfeeding in Vietnam 
[95], which may lead to a corresponding lack of protection against pathogens such as 
Shigella in this population. Therefore encouragement of exclusive breastfeeding for as 
long as possible is important in HCMC. WASH-based interventions are also effective 
[28–32], although again required sustained funding and political support. Finally, 
optimising therapy, particularly in the face of growing fluoroquinolone resistance, will help 
to prevent onward spread of infection.  
11.8 Limitations 
One of the major limitations of this thesis is the lack of generalisability of data collected in 
HCMC to greater Vietnam. HCMC is the country’s largest, wealthiest city, and although it 
has a large number of poor, inner-city slum residents [96], the demographics and 
urbanised nature of the city make it dissimilar to the majority of the country [97]. In 
Chapter Five, for example, the rates and aetiologies of diarrhoeal disease were 
significantly different between urban HCMC and rural Dong Thap province (120km 
southwest of HCMC). Though Dong Thap and the surrounding the Mekong River Delta 
region (one of eight in the country) have a higher rate of poverty (10.3%, defined as a 
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per capita expenditure of less than US$10/month) compared to the Southeast Region of 
HCMC (5.8%), there are regions in Vietnam such as the Northwest Mountains (49%) and 
Central Highlands (29%) that have far greater levels of poverty [98]. So although the 
burden of Shigella in HCMC is not substantial enough to justify a vaccine programme, 
the epidemiological situation of diarrhoeal disease is likely to be dramatically different 
outside of HCMC. Whether a Shigella vaccine is warranted in rural Vietnam cannot be 
addressed through data in this thesis.    
An additional limitation includes the lack of diagnostic consistency across the different 
studies included in the thesis. Ideally, the Luminex platform would have been available 
for use at all timepoints to allow for consistent comparisons. However due to the 
expense (US$75/sample) this was not feasible. Finally, as shown in Chapter Eight, the 
bulk (57%) of diarrhoeal episodes are not seen in hospital in HCMC. Therefore it is likely 
that the majority of the work presented in this thesis is biased by healthcare-seeking 
behaviour. The reported results, particularly for Chapters Three, Four and Five, therefore 
pertain to those who are able to seek healthcare and who are likely wealthier and 
epidemiologically otherwise different to those children and families who could not attend 
healthcare. The cohort in Chapter Eight and relevant data in Chapter Nine should not be 
as biased due to active surveillance. Additionally, though considerable effort was made 
to collect disease information, we cannot guarantee that we were able to capture every 
diarrhoeal episode throughout the cohort, which may lead to an underestimated 
incidence measurement. Regardless, the work presented in this thesis presents the most 
comprehensive epidemiological evaluation of diarrhoeal disease and Shigella in HCMC 
to date, and is likely representative of other rapidly developing cities in the region.   
11.9 Alternative approaches and future directions 
Several alternative approaches to determine the epidemiology of diarrhoeal disease and 
evaluate the need of a Shigella vaccine could have been employed. Active surveillance 
in infancy would have allowed for more robust incidence calculations for an age group 
where infection can often be severe [9]. Additionally, though there is evidence of a 
demand for a vaccine against shigellosis/dysentery from parents of young children in 
East Asia [99], an evaluation of local physician attitudes toward the need for such a 
vaccine in this setting would have led to useful insight on the burden and perceived 
severity of the syndrome by local healthcare workers. Such work would have broadened 
the scope of the evaluation beyond just the hospital and districts directly included in the 
thesis.  
221 
 
Common transmission pathways of Shigella in the HCMC context remains an 
unanswered question. Whether transmission occurs predominately via person-to-person 
contact [100–103], via contaminated water supplies [104,105] or a combination of both is 
unclear. Two additional avenues of investigation would aid in generating evidence to 
answer this question. First, environmental sampling of local drinking water supplies 
would permit identification and quantification of Shigella DNA, as was done to investigate 
the prevalence of organisms causing typhoid fever in Kathmandu, Nepal [106]. Sampling 
of a variety of water sources, such as wells, the municipal supply and purchased bottled 
water is recommended. To investigate person-to-person transmission, a study evaluating 
in-household transmission of Shigella would be invaluable. By identifying index cases in 
hospital and subsequently enrolling and sampling family members, secondary attack 
rates could be estimated [107]. Whole genome sequencing of organisms, both from 
water supplies as well as from in-household transmission investigations, would allow for 
more robust conclusions as to likely transmission pathways [108]. An enhanced 
understanding of transmission pathways would aid in targeting non-vaccine based 
interventions in HCMC.  
In the future, additional investigations into the epidemiology of diarrhoeal disease and 
Shigella in locations in Vietnam other than HCMC would be beneficial. Study sites in 
rural locations, for example, or in predominately minority regions would help to better 
inform policy decisions regarding diarrhoeal disease for the country as a whole. There is 
a large, ongoing study through the Oxford University Clinical Research Unit (OUCRU) 
that is examining the aetiology and prevalence of a number of common syndromes in 
Vietnam, including diarrhoeal disease, in six different locations to investigate zoonotic 
infections [109]. With over 3,000 diarrhoeal samples projected to be collected across a 
number of epidemiologically variable locations, such a study presents an unprecedented 
opportunity to examine geographic and socioeconomic differences in the aetiology of 
diarrhoeal disease in Vietnam. Furthermore, this data will likely highlight areas at 
increased risk for Shigella infections in which future research could take place.  
Next, evaluating the prevalence of diarrhoeal pathogens in non-diarrhoeal stool samples 
from the cohort will provide important evidence on the relative pathogenicity of 
organisms identified by the Luminex platform. As mentioned, both the GEMS and MAL-
ED studies identified a number of aetiologies (aEPEC, Giardia etc) frequently in healthy 
stool [39,40]. A pathogenicity index for HCMC specifically will help to inform clinical 
therapeutic decisions in this setting. Furthermore, the cohort will provide for an 
evaluation of longitudinal immune responses to a number of Shigella antigens in children 
which can aid in informing future vaccine trials [110].  
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Finally, one of the directions for future research derived from this thesis is the need for 
rapid diagnostics that are universally accessible [111]. Doctors in public hospitals in 
HCMC still rely on microbiological culture and subsequent drug sensitivity testing, which 
can take up to five days to complete. As the median length of stay of children with 
diarrhoea in hospitals in HCMC is five days [112], the need for faster diagnostics is clear. 
The low sensitivity of microbiological culture demonstrated in Chapter Eight is likely due 
to high use of antimicrobials in the community prior to clinical consultations [21,113], and 
calls for more sensitive techniques to be employed. An ideal enteric diagnostic test for 
settings such as HCMC would need to be inexpensive, easy to use, fast, refrigeration-
free, transportable, cover a wide variety of pathogens and have high sensitivity and 
specificity [114,115].  Effective multiplex molecular techniques, such as the Luminex 
platform, are available [44,116–118]. However, the cost (US$75/reaction) of the Luminex 
platform is prohibitive for government hospital use in HCMC. Some progress has been 
made into techniques, such as PCR, that have been adapted for low-resource settings 
[119]. With a lack of a vaccine and large hurdles in improving socioeconomic status, 
identification and prompt and appropriate therapy is currently one of the most feasible 
manners in which to reduce morbidity and transmission due to Shigella in endemic 
areas. 
11.10 Conclusions 
The cohort study developed in this thesis will continue to provide important information 
regarding Shigella diarrhoeal disease in an industrialising setting as the children mature. 
A detailed risk factor analysis during the period of known burden of Shigella infections 
(two to three years of age) with a full, complete dataset is hoped to provide specific 
information on potential routes of transmission to generate tangible and targeted 
prevention activities. It is known that Shigella is commonly transmitted person-to-person 
[10,120,121], but through the cohort we are aiming to identify the important groups 
involved in transmission, whether it be in schools, between older or younger siblings in 
the home or potentially due to contact with grandparents, who are often the caretakers of 
children in HCMC and have been found to present commonly with Shigella in China 
[122]. An integrated approach using evidence-based prevention measures, including 
promotion of breastfeeding in the community in HCMC would serve to prevent morbidity 
due to a variety of diarrhoeal pathogens, including Shigella [123], in the absence of a 
vaccine programme.  
In conclusion, diarrhoeal disease is a public health challenge in HCMC. Low rotavirus 
vaccine uptake and a dramatic increase in antimicrobial resistance against first- and 
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second-line therapies in bacterial agents such as Shigella are driving the continued 
persistence of morbidity in young children in this setting. Affordable and accurate 
diagnostics and targeted prevention measures in settings such as HCMC would help to 
alleviate short- and long-term suffering due to diarrhoeal disease in young children, 
particularly among poor, inner-city communities. A future Shigella vaccine, though not 
necessary in HCMC at this time, would greatly aid in reducing the burden of disease 
globally, particularly in the face of rampant AMR.  
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